Cabometyx (cabozantinib tablet) / Exelixis 
Welcome,         Profile    Billing    Logout  
 64 Diseases   145 Trials   145 Trials   4880 News 
219 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Cabometyx (cabozantinib tablet) / Exelixis
2018-003954-26: CYP3A4*22 genotype-guided dosing of TKIs in cancer patients: a new way of personalized therapy Op basis van CYP3A4*22 genotype doseren van tyrosine-kinase remmers bij patiënten met kanker: een nieuwe manier van gepersonaliseerde therapie.

Not yet recruiting
4
198
Europe
Film-coated tablet, Capsule, hard, Coated tablet, Tablet, Cabozantinib/Cabometyx, Cobimetinib/Cotellic, Dabrafenib/Tafinlar, Dasatinib/Sprycel, Erlotinib/Tarceva, Everolimus/Afinitor/Votubia, Imatinib, Lapatinib/Tyverb, Nilotinib/Tasigna, Olaparib/Lynparza, Palbociclib/Ibrance, Ponatinib/Iclusig, Regorafenib/Stivarga, Ruxolitinib/Jakavi, Sunitinib/Sutent, Pazopanib/Votrient, Cabozantinib/Cometriq, Olaparib?Lynparza, Brigatinib - Alunbrig, Encorafenib - Braftovi, Osimertinib/Tagrisso
Erasmus MC Cancer Institute, Erasmus MC
Patients diagnosed with a neoplasm and treated with a tyrosine kinase inhibitor which is mainly metabolised by CYP3A4. Patienten gediagnosticeerd met een maligniteit en behandeld met een tyrosine kinase inhibitor welke voornamelijk wordt gemetaboliseerd door CYP3A4., Patients diagnosed with cancer and treated with a TKI. Patienten gediagnosticeerd met kanker en behandeld met een TKI., Diseases [C] - Cancer [C04]
 
 
EXAMINER, NCT01896479 / 2013-003402-40: A Study of Two Different Doses of Cabozantinib (XL184) in Progressive, Metastatic Medullary Thyroid Cancer

Active, not recruiting
4
247
Europe, Canada, RoW
Cabozantinib (XL184) 140 mg, Cabozantinib (XL184) 60 mg, Placebo tablet, Placebo capsule
Exelixis
Medullary Thyroid Cancer
07/20
12/23
CABOLD, NCT06934057: Cabozantinib and Nivolumab Among Older Patients With Renal Cell Carcinoma

Not yet recruiting
4
50
Europe
Nivolumab, OPDIVO, Cabozantinib, CABOMETYX
Gustave Roussy, Cancer Campus, Grand Paris, Ipsen
Kidney Cancer, Renal Cell Cancer
04/28
04/28
CheckMate 9ER, NCT03141177 / 2017-000759-20: A Study of Nivolumab Combined With Cabozantinib Compared to Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma

Hourglass Jun 2023 - Jun 2023 : 3 year quality-of-life follow-up data from CheckMate -9ER trial in 1L RCC at ASCO 2023
Checkmark Data from CheckMate 9ER trial in combination with Cabometyx/Yervoy in 1L RCC at IKCS 2022
Jun 2022 - Jun 2022: Data from CheckMate 9ER trial in combination with Cabometyx/Yervoy in 1L RCC at IKCS 2022
Checkmark Exploratory analysis data in combination with Opdivo vs sunitinib for advanced 1L RCC based on CheckMate 9ER study at ASCO 2022
Jun 2022 - Jun 2022: Exploratory analysis data in combination with Opdivo vs sunitinib for advanced 1L RCC based on CheckMate 9ER study at ASCO 2022
More
Active, not recruiting
3
701
Europe, Japan, US, RoW
Nivolumab, Opdivo, BMS-936558, Cabozantinib, Cabometyx, Sunitinib, Sutent, Ipilimumab, Yervoy, BMS-734016
Bristol-Myers Squibb, Exelixis, Ono Pharmaceutical Co. Ltd
Renal Cell Carcinoma
02/20
04/24
COSMIC-311, NCT03690388 / 2018-001771-21: A Study of Cabozantinib Compared With Placebo in Subjects With Radioiodine-refractory Differentiated Thyroid Cancer Who Have Progressed After Prior Vascular Endothelial Growth Factor Receptor (VEGFR) -Targeted Therapy

Checkmark Approved in Brazil for the treatment of differentiated thyroid cancer based on COSMIC-311 trial
Dec 2022 - Dec 2022: Approved in Brazil for the treatment of differentiated thyroid cancer based on COSMIC-311 trial
Checkmark Results for prespecified subgroups based on baseline histology subtypes of papillary & follicular thyroid cancers based on COSMIC-311 study at ASCO 2022
May 2022 - May 2022: Results for prespecified subgroups based on baseline histology subtypes of papillary & follicular thyroid cancers based on COSMIC-311 study at ASCO 2022
Checkmark Results from prespecified subgroups who received prior lenvatinib and/or sorafenib treatment for differentiated thyroid cancer based on COSMIC-311 study at ASCO 2022
More
Active, not recruiting
3
187
Europe, Canada, US, RoW
Cabozantinib, XL184, Cabometyx®, Placebo
Exelixis, Ipsen
Differentiated Thyroid Cancer
08/20
12/24
COSMIC-312, NCT03755791 / 2018-003354-24: Study of Cabozantinib in Combination With Atezolizumab Versus Sorafenib in Subjects With Advanced HCC Who Have Not Received Previous Systemic Anticancer Therapy

Hourglass Jul 2022 - Dec 2022 : Market entry in combination with Tecentriq for 1L liver cancer (based on COSMIC-312 trial)
Checkmark Final data from COSMIC-312 trial in combination with Tecentriq for 1L HCC
Mar 2022 - Mar 2022: Final data from COSMIC-312 trial in combination with Tecentriq for 1L HCC
Not Appicable Jan 2022 - Mar 2022 : Submission for 1L HCC
Checkmark Presentation of data from COSMIC-312 trial in combination with Tecentriq for 1L HCC at ESMO Asia 2021
More
Active, not recruiting
3
837
Europe, Canada, US, RoW
Cabozantinib, XL184, Cabometyx®, Sorafenib, Nexavar®, Atezolizumab, Tecentriq®
Exelixis
Hepatocellular Carcinoma
03/21
12/24
2021-000615-23: Study comparing the standard administration of immunotherapy (IO) versus the same agent administered each three months in patients with metastatic cancer in response after 6 months of standard IO

Not yet recruiting
3
646
Europe
pembrolizumab, durvalumab, atezolizumab, avelumab, bevacizumab, pemetrexed, cabozantinib, Concentrate for solution for infusion, Powder for concentrate for solution for infusion, Film-coated tablet, OPDIVO, KEYTRUDA, IMFINZI, Tecentriq, Bavencio
UNICANCER, PHRC-K 2020, Fondation BMS
Oncologic metastatic tumour (lung cancer (K), renal cell K (except IMDC favorable-risk treated TKI / immunotherapy [IO] combination), head and neck K, bladder K, triple negative breast K, Merkel K and melanoma, or hepatocellular carcinoma) in PR or CR (except for melanoma, only patients in partial response) after 6 months of standard IO treatment (monotherapy or previously in combination with other immunotherapy or chemotherapy or continuous combination with pemetrexed or bevacizumab or TKI)., -, Diseases [C] - Cancer [C04]
 
 
COSMIC-313, NCT03937219 / 2018-004567-31: Study of Cabozantinib in Combination With Nivolumab and Ipilimumab in Patients With Previously Untreated Advanced or Metastatic Renal Cell Carcinoma

Feb 2023 - Dec 2023: Overall survival analysis data from COSMIC-313 trial in combination with opdivo and yervoy for advanced 1L RCC
Checkmark Detailed results from COSMIC-313 trial in combination with Opdivo and Yervoy for RCC
Sep 2022 - Sep 2022: Detailed results from COSMIC-313 trial in combination with Opdivo and Yervoy for RCC
Checkmark Top-line data from COSMIC-313 trial in combination with Opdivo and Yervoy for 1L RCC at ESMO 2022
Sep 2022 - Sep 2022: Top-line data from COSMIC-313 trial in combination with Opdivo and Yervoy for 1L RCC at ESMO 2022
More
Active, not recruiting
3
855
Europe, Canada, US, RoW
Cabozantinib, Cabometyx, XL184, Nivolumab, Opdivo, BMS-936558, Ipilimumab, Yervoy, BMS-734016, Cabozantinib-matched placebo
Exelixis
Renal Cell Carcinoma
01/22
06/26
CONTACT-01, NCT04471428 / 2020-000100-11: Study of Atezolizumab in Combination With Cabozantinib Versus Docetaxel in Patients With Metastatic Non-Small Cell Lung Cancer Previously Treated With an Anti-PD-L1/PD-1 Antibody and Platinum-Containing Chemotherapy

Checkmark CONTACT-01 study in combination with Tecentriq for 2L NSCLC did not meet its primary endpoint of overall survival at the final analysis
Dec 2022 - Dec 2022: CONTACT-01 study in combination with Tecentriq for 2L NSCLC did not meet its primary endpoint of overall survival at the final analysis
Completed
3
366
Europe, Japan, US, RoW
Cabozantinib, Atezolizumab, Tecentriq, Docetaxel
Hoffmann-La Roche, Exelixis
Carcinoma, Non-Small-Cell Lung
09/22
01/25
CONTACT-03, NCT04338269 / 2020-000502-29: A Study of Atezolizumab in Combination With Cabozantinib Compared to Cabozantinib Alone in Participants With Advanced Renal Cell Carcinoma After Immune Checkpoint Inhibitor Treatment

Jan 2023 - Jun 2023: Top-line data readout from CONTACT-03 trial in combination with Tecentriq for advanced or metastatic RCC
Checkmark Enrollment is complete for CONTACT-03 study in combination with Tecentriq for locally advanced/metastatic clear cell/non-clear cell (papillary or unclassified only) 1L RCC
Jan 2022 - Jan 2022: Enrollment is complete for CONTACT-03 study in combination with Tecentriq for locally advanced/metastatic clear cell/non-clear cell (papillary or unclassified only) 1L RCC
Checkmark CONTACT-03 phase 3 pivotal trial initiation in combination with Tecentriq for 2L RCC
Jul 2020 - Jul 2020: CONTACT-03 phase 3 pivotal trial initiation in combination with Tecentriq for 2L RCC
Completed
3
522
Europe, Canada, Japan, US, RoW
Atezolizumab, Tecentriq, Cabozantinib, Cabometyx
Hoffmann-La Roche, Exelixis, Chugai Pharmaceutical
Carcinoma, Renal Cell
01/23
03/25
LIBRETTO-531, NCT04211337 / 2019-001978-28: A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid Cancer

Active, not recruiting
3
291
Europe, Canada, Japan, US, RoW
Selpercatinib, LY3527723, LOXO-292, Cabozantinib, Vandetanib
Loxo Oncology, Inc., Eli Lilly and Company
Medullary Thyroid Cancer
05/23
02/26
CONTACT-2, NCT04446117 / 2020-000348-77: Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC

Hourglass Feb 2024 - Mar 2024 : FY'23 - Submission in Japan for CRPC (based on CONTACT-02 study)
Jan 2023 - Dec 2023: From CONTACT-02 trial in combination with Cabometyx for metastatic CRPC
Jan 2023 - Dec 2023: From trial in combination with Tecentriq for mCRPC
Hourglass Jan 2023 - Jun 2023 : Completion of enrollment of P3 CONTACT-02 trial in combination with Tecentriq for metastatic CRPC
Active, not recruiting
3
575
Europe, Canada, Japan, US, RoW
Cabozantinib, XL184, Cabometyx®, Atezolizumab, Tecentriq®, Abiraterone Acetate, Abiraterone, Zytiga, Enzalutamide, Xtandi, Prednisone
Exelixis, Roche-Genentech, Takeda
Metastatic Prostate Cancer, Prostate Adenocarcinoma
04/24
10/26
CARE1, NCT06364631: Pragmatic Clinical Trial

Recruiting
3
1250
Europe, RoW
Nivolumab, OPDIVO, Ipilimumab, YERVOY, Pembrolizumab, KEYTRUDA, Cabozantinib, CABOMETYX, Axitinib, INLYTA, Lenvatinib, LENVIMA
Gustave Roussy, Cancer Campus, Grand Paris, European Commission, CRIS Cancer Foundation, National Cancer Institute, France, Rennes University Hospital, University Hospital, Essen, Fundació Privada Institut d'Investigació Oncològica de Vall d'Hebron, The Netherlands Cancer Institute, Servicio Madrileño de Salud, Madrid, Spain, Hospital Universitario 12 de Octubre, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Medical University of Vienna, FAKULTNI NEMOCNICE OLOMOUC, International Kidney Cancer Coalition, Association pour la Recherche sur les Tumeurs du Rein, Resilience, PRIMAA, Queen Mary University of London
Metastatic Kidney Cancer, Metastatic Kidney Carcinoma
05/32
05/32
NCT06475989: Study of Targeted Therapy vs. Chemotherapy in Patients With Thyroid Cancer

Recruiting
3
264
US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Cabozantinib, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Dabrafenib, BRAF Inhibitor GSK2118436, GSK-2118436, GSK-2118436A, GSK2118436, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Questionnaire Administration, Trametinib, GSK 1120212, GSK-1120212, GSK1120212, JTP-74057, MEK Inhibitor GSK1120212
ECOG-ACRIN Cancer Research Group, National Cancer Institute (NCI)
Refractory Differentiated Thyroid Gland Carcinoma
09/30
09/30
PDIGREE, NCT03793166: Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The Study

Checkmark Initiated in combination with nivolumab and ipilimumab for 1L RCC
Jan 2019 - Jan 2019: Initiated in combination with nivolumab and ipilimumab for 1L RCC
Active, not recruiting
3
1175
US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Bone Scan, Bone Scintigraphy, Cabozantinib, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Ipilimumab, Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, BMS 734016, BMS-734016, BMS734016, Ipilimumab Biosimilar CS1002, MDX 010, MDX-010, MDX-CTLA4, MDX010, Yervoy, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Nivolumab, ABP 206, BCD-263, BMS 936558, BMS-936558, BMS936558, CMAB819, MDX 1106, MDX-1106, MDX1106, NIVO, Nivolumab Biosimilar ABP 206, Nivolumab Biosimilar BCD-263, Nivolumab Biosimilar CMAB819, ONO 4538, ONO-4538, ONO4538, Opdivo, Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration
National Cancer Institute (NCI)
Clear Cell Renal Cell Carcinoma, Metastatic Malignant Neoplasm in the Bone, Metastatic Malignant Neoplasm in the Lymph Nodes, Metastatic Malignant Neoplasm in the Soft Tissue, Metastatic Malignant Neoplasm in the Viscera, Rhabdoid Tumor of the Kidney, Sarcomatoid Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8
09/25
09/25
STROKER, NCT06726421: Systemic Therapy Alone or with Stereotactic Body Radiotherapy for Oligometastatic Kidney Cancer ( Study)

Recruiting
3
252
RoW
Stereotactic body radiotherapy (SBRT), Stereotactic ablative radiotherapy, axitinib ± immune checkpoint inhibitors (ICIs), lenvatinib ± ICIs, cabozantinib ± ICIs, sunitinib and pazopanib, Standard systemic therapy
Sun Yat-sen University
Renal Cell Carcinoma (Kidney Cancer), Kidney Cancer Metastatic, Renal Cell Carcinoma Metastatic
09/30
09/33
MAIN-CAV, NCT05092958: Testing the Addition of the Anti-cancer Drug, Cabozantinib, to the Usual Immunotherapy Treatment, Avelumab, in Patients With Metastatic Urothelial Cancer, Study

Active, not recruiting
3
654
Canada, US
Avelumab, Bavencio, MSB 0010718C, MSB-0010718C, MSB0010718C, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Bone Scan, Bone Scintigraphy, Cabozantinib S-malate, BMS-907351, Cabometyx, Cometriq, XL 184, XL-184, XL184, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration
National Cancer Institute (NCI)
Advanced Bladder Urothelial Carcinoma, Advanced Renal Pelvis Urothelial Carcinoma, Advanced Ureter Urothelial Carcinoma, Advanced Urethral Urothelial Carcinoma, Metastatic Bladder Urothelial Carcinoma, Metastatic Renal Pelvis Urothelial Carcinoma, Metastatic Ureter Urothelial Carcinoma, Metastatic Urethral Urothelial Carcinoma, Stage III Bladder Cancer AJCC v8, Stage III Renal Pelvis and Ureter Cancer AJCC v8, Stage III Renal Pelvis Cancer AJCC v8, Stage III Ureter Cancer AJCC v8, Stage III Urethral Cancer AJCC v8, Stage IV Bladder Cancer AJCC v8, Stage IV Renal Pelvis and Ureter Cancer AJCC v8, Stage IV Renal Pelvis Cancer AJCC v8, Stage IV Ureter Cancer AJCC v8, Stage IV Urethral Cancer AJCC v8
12/25
12/25
CABINET, NCT03375320: Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tumors

Hourglass Feb 2020 - Dec 2020 : Data from CABINET trial for advanced NET
Active, not recruiting
3
298
US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Cabozantinib S-malate, BMS-907351, Cabometyx, Cometriq, XL 184, XL-184, XL184, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Placebo Administration, Quality-of-Life Assessment, Quality of Life Assessment, X-Ray Imaging, Conventional X-Ray, Diagnostic Radiology, Medical Imaging, X-Ray, Plain film radiographs, Radiographic Imaging, Radiographic imaging procedure (procedure), Radiography, RG, Static X-Ray, X-Ray
National Cancer Institute (NCI)
Carcinoid Tumor, Functioning Pancreatic Neuroendocrine Tumor, Intermediate Grade Lung Neuroendocrine Neoplasm, Locally Advanced Digestive System Neuroendocrine Neoplasm, Locally Advanced Digestive System Neuroendocrine Tumor G1, Locally Advanced Lung Neuroendocrine Neoplasm, Locally Advanced Pancreatic Neuroendocrine Tumor, Locally Advanced Unresectable Digestive System Neuroendocrine Neoplasm, Low Grade Lung Neuroendocrine Neoplasm, Lung Neuroendocrine Tumor, Lung Neuroendocrine Tumor G2, Metastatic Digestive System Neuroendocrine Neoplasm, Metastatic Digestive System Neuroendocrine Tumor G1, Metastatic Lung Neuroendocrine Neoplasm, Metastatic Lung Neuroendocrine Tumor, Metastatic Pancreatic Neuroendocrine Neoplasm, Metastatic Pancreatic Neuroendocrine Tumor, Metastatic Thymus Neuroendocrine Neoplasm, Neuroendocrine Neoplasm, Neuroendocrine Tumor G2, Non-Functioning Pancreatic Neuroendocrine Tumor, Pancreatic Serotonin-Producing Neuroendocrine Tumor, Thymus Neuroendocrine Tumor, Unresectable Digestive System Neuroendocrine Neoplasm, Unresectable Digestive System Neuroendocrine Tumor G1, Unresectable Lung Neuroendocrine Neoplasm, Unresectable Pancreatic Neuroendocrine Neoplasm, Unresectable Thymus Neuroendocrine Neoplasm
08/23
11/25
LITESPARK-011, NCT04586231 / 2020-002075-35: A Study of Belzutifan (MK-6482) in Combination With Lenvatinib Versus Cabozantinib for Treatment of Renal Cell Carcinoma (MK-6482-011)

Active, not recruiting
3
708
Europe, Canada, Japan, US, RoW
Belzutifan, PT2977, MK-6482, WELIREG™, Lenvatinib, Lenvima, E7080, MK-7902, Cabozantinib, Cabometyx, Cometriq, XL184, BMS-907351
Merck Sharp & Dohme LLC, Eisai Inc.
Carcinoma, Renal Cell
02/26
02/27
AcceleRET-MTC, NCT04760288 / 2020-005269-15: A Study of Pralsetinib Versus Standard of Care (SOC) for Treatment of RET-Mutated Medullary Thyroid Cancer (MTC).

Withdrawn
3
198
Europe
Pralsetinib, Cabozantinib, Vandetanib
Hoffmann-La Roche
Medullary Thyroid Cancer
10/27
04/35
IMbrella B, NCT03768063 / 2018-003352-20: A Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study

Active, not recruiting
3
1000
Europe, Japan, US, RoW
Atezolizumab, Tecentriq, Bevacizumab, Avastin, Alectinib, Alecensa, Cobimetinib, Cotellic, Vemurafenib, Zelboraf, FAP IL2V, simlukafusp alfa, Venetoclax, Venclexta, Enzalutamide, Xtandi, Pembrolizumab, Keytruda, Sunitinib, Sutent, Niraparib, Zejula, Cabozantinib, Cometriq, Pemetrexed, Paclitaxel, Emactuzumab, Rucaparib
Hoffmann-La Roche, F. Hoffmann-La Roche Ltd, F. Hoffmann- La Roche Ltd
Cancer
07/28
07/28
NCT05683197: A Study to Test the Addition of the Drug Cabozantinib to Chemotherapy in Patients With Newly Diagnosed Osteosarcoma

Not yet recruiting
2/3
1122
NA
Cabozantinib S-malate, 1140909-48-3, BMS-907351, Butanedioic acid, 2-hydroxy-, (2S)-, compd. with N-[4-[(6,7-dimethoxy-4-quinolinyl)oxy]phenyl]-N'-(4-fluorophenyl)-1, 1-cyclopropanedicarboxamide (1:1), Cabometyx, Cometriq, XL-184, XL184, Methotrexate, 4-Amino-10-methylfolic Acid, 4-Amino-4-deoxy-10-methylpteroyl-L-glutamic Acid, 59-05-2, Abitrexate, Alpha-Methopterin, Amethopterin, Brimexate, CL 14377, CL-14377, Farmitrexat, Fauldexato, Folex, Folex PFS, Lantarel, Ledertrexate, Lumexon, Maxtrex, Medsatrexate, Metex, Methoblastin, Methotrexate LPF, Methylaminopterin, Methotrexatum, Metrotex, Mexate, Mexate-AQ, MTX, N-[4-[[(2,4-Diamino-6-pteridinyl)methyl]methylamino]benzoyl]-L-glutamic Acid, Novatrex, Rheumatrex, Texate, Tremetex, Trexeron, Trixilem, WR-19039, Doxorubicin Hydrochloride, 14-Hydroxydaunorubicin Hydrochloride, 25316-40-9, 3-Hydroxyacetyldaunorubicin Hydrochloride, 12-Naphthacenedione, 6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7, 10-[(3-amino-2,3,,10-tetrahydro-6, 11-trihydroxy-8-hydroxyacetyl)-1-methoxy-, hydrochloride, (8S-cis)- (9CI), Cisplatin, (SP-4-2)-Diamminedichloroplatinum, 15663-27-1, Abiplatin, Blastolem, Briplatin, CDDP, Cis-diammine-dichloroplatinum, X-Ray Imaging, Computed Tomography, Magnetic Resonance Imaging, Bone Scan
Children's Oncology Group, National Cancer Institute (NCI)
Localized Osteosarcoma, Metastatic Osteosarcoma, Resectable Osteosarcoma, Unresectable Osteosarcoma
03/30
03/30
NCT05691478: A Study to Test the Addition of the Drug Cabozantinib to Chemotherapy in Patients With Newly Diagnosed Osteosarcoma

Suspended
2/3
1122
US
Bone Scan, Bone Scintigraphy, Cabozantinib S-malate, BMS-907351, Cabometyx, Cometriq, XL 184, XL-184, XL184, Cisplatin, Abiplatin, Blastolem, Briplatin, CDDP, Cis-diammine-dichloroplatinum, Cis-diamminedichloridoplatinum, Cis-diamminedichloro Platinum (II), Cis-diamminedichloroplatinum, Cis-dichloroammine Platinum (II), Cis-platinous Diamine Dichloride, Cis-platinum, Cis-platinum II, Cis-platinum II Diamine Dichloride, Cismaplat, Cisplatina, Cisplatinum, Cisplatyl, Citoplatino, Citosin, Cysplatyna, DDP, Lederplatin, Metaplatin, Neoplatin, Peyrone's Chloride, Peyrone's Salt, Placis, Plastistil, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platinol- AQ, Platinol-AQ, Platinol-AQ VHA Plus, Platinoxan, Platinum, Platinum Diamminodichloride, Platiran, Platistin, Platosin, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Doxorubicin Hydrochloride, 5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8, 9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, hydrochloride, (8S-cis)- (9CI), ADM, Adriacin, Adriamycin, Adriamycin Hydrochloride, Adriamycin PFS, Adriamycin RDF, ADRIAMYCIN, HYDROCHLORIDE, Adriamycine, Adriblastina, Adriblastine, Adrimedac, Chloridrato de Doxorrubicina, DOX, DOXO-CELL, Doxolem, Doxorubicin HCl, Doxorubicin.HCl, Doxorubin, Farmiblastina, FI 106, FI-106, FI106, hydroxydaunorubicin, Rubex, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Methotrexate, Abitrexate, Alpha-Methopterin, Amethopterin, Brimexate, CL 14377, CL-14377, Emtexate, Emthexat, Emthexate, Farmitrexat, Fauldexato, Folex, Folex PFS, Jylamvo, Lantarel, Ledertrexate, Lumexon, Maxtrex, Medsatrexate, Metex, Methoblastin, Methotrexate LPF, Methotrexate Methylaminopterin, Methotrexatum, Metotrexato, Metrotex, Mexate, Mexate-AQ, MTX, Novatrex, Rheumatrex, Texate, Tremetex, Trexeron, Trixilem, WR-19039, Surgical Procedure, Operation, Surgery, Surgery Type, Surgery, NOS, Surgical, Surgical Intervention, Surgical Interventions, Surgical Procedures, Type of Surgery, X-Ray Imaging, Conventional X-Ray, Diagnostic Radiology, Medical Imaging, X-Ray, Plain film radiographs, Radiographic Imaging, Radiographic imaging procedure (procedure), Radiography, RG, Static X-Ray, X-Ray
National Cancer Institute (NCI)
High Grade Osteosarcoma, Localized Osteosarcoma, Metastatic Osteosarcoma, Secondary Osteosarcoma
03/30
03/30
jRCTs011210055: Cabozantinib ePRO study

Completed
2
105
Japan
Cabometyx (cabozantinib tablet) - Exelixis
Hokkaido University Hospital, Takeda Pharmaceutical Company Limited
Renal cell carcinoma
 
 
2013-000762-11: A randomized double-blind phase II study evaluating the role of maintenance therapy with cabozantinib in High Grade Uterine Sarcoma (HGUtS) after stabilization or response to doxorubicin +/- ifosfamide following surgery or in metastatic first line treatment

Ongoing
2
90
Europe, RoW
Cabozantinib, XL184, Film-coated tablet
European Organisation for Research and Treatment of Cancer (EORTC), Exelixis, European Organisation for Research and Treatment of Cancer (EORTC)
High Grade Undifferentiated Uterine Sarcoma (HGUS), Uterine Sarcoma, Diseases [C] - Cancer [C04]
 
 
NCT01815151: A Study of XL184 (Cabozantinib) in Endometrial Cancer

Not yet recruiting
2
36
Canada
XL-184, Cabozantinib
University Health Network, Toronto, National Cancer Institute (NCI)
Metastatic, Endometrial Cancer, Endometrioid, Serous, Mix Histology, Carcinosarcoma, Clear Cell, Adenosquamous
04/15
09/15
NCT01708954: Erlotinib Hydrochloride and Cabozantinib-s-Malate Alone or in Combination as Second or Third Line Therapy in Treating Patients With Stage IV Non-small Cell Lung Cancer

Checkmark Data from E1512 study in 2L or 3L EGFR wild-type NSCLC at ASCO
May 2015 - May 2015: Data from E1512 study in 2L or 3L EGFR wild-type NSCLC at ASCO
Checkmark In EGFR-wild type NSCLC
Nov 2014 - Nov 2014: In EGFR-wild type NSCLC
Checkmark From Eastern Cooperative Oncology Group trial in second line or third line EGFR wild type NSCLC
More
Active, not recruiting
2
125
US
Cabozantinib S-malate, BMS-907351, Cabometyx, Cometriq, XL 184, XL-184, XL184, Erlotinib Hydrochloride, CP 358, CP-358, Cp-358,774, CP358, OSI 774, OSI-774, OSI774, Tarceva, Laboratory Biomarker Analysis
National Cancer Institute (NCI)
Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Non-Small Cell Cancer AJCC v7
08/15
03/26
NCT02036476: Cabozantinib in Recurrent/Metastatic Merkel Cell Carcinoma

Terminated
2
8
US
Cabozantinib, XL184, Cometriq
Dana-Farber Cancer Institute, Exelixis
Merkel Cell Carcinoma, Skin Cancer
04/16
07/16
2017-003103-22: Advanced or Metastatic Collecting ducts renal cell carcinoma Cabozantinib nel carcinoma renale dei dotti collettori di Bellini.

Not yet recruiting
2
23
Europe
Film-coated tablet, CABOMETYX
FONDAZIONE IRCCS "ISTITUTO NAZIONALE DEI TUMORI", IPSEN S.p.A.
Collecting Duct Renal Cell Carcinoma Carcinoma renale dei dotti collettori di Bellini (CDC), Collecting Duct Renal Cell Carcinoma Carcinoma renale dei dotti collettori di Bellini (CDC), Diseases [C] - Cancer [C04]
 
 
2018-000682-36: cabozantinib for salivary gland cancer patients cabozantinib voor speekselklierkanker

Ongoing
2
43
Europe
Cabometyx, Tablet, Cabometyx
Radboud university medical center, Ipsen
Salivary gland cancer Speekselklierkanker, salivary gland cancer Speekselklierkanker, Diseases [C] - Cancer [C04]
 
 
2018-001201-93: Clinical trial for the evaluation of a new drug (cabozantinib) treatment given before having kidney surgery in patients with kidney cancer that is advanced or has spread Ensayo clínico para la evaluación de un nuevo tratamiento farmacológico (cabozantinib) administrado antes de una cirugía renal en pacientes con cáncer de riñón que está avanzado o se ha diseminado

Ongoing
2
50
Europe
Cabometyx, XL184, Film-coated tablet, Cabometyx
Fundación ONCOSUR, Ipsen Pharma
Locally Advanced or Metastatic Renal Cell Carcinoma Cáncer de células renales localmente avanzado o metastásico, Patients with Kidney Cancer that is advanced or that has spread. Pacientes con cáncer de riñón avanzado o que se ha extendido, Diseases [C] - Cancer [C04]
 
 
NCT06377722: Cabozantinib Treatment Prior to Cytoreductive Nephrectomy in Patients With Advanced or Metastatic Renal Cells Cancer

Terminated
2
18
Europe
Cabozantinib, No other intervention names
Fundacion Oncosur
Renal Cell Carcinoma Metastatic, Renal Cell Carcinoma Stage IV, Renal Cell Carcinoma Stage III
08/22
08/22
2018-002948-88: Phase II study with Cabozantinib in patients with RET positive NSCLC Studio di fase II con Cabozantinib in pazienti con NSCLC RET positivo

Ongoing
2
25
Europe
CABOMETYX, [NA], Tablet, CABOMETYX - 20 MG- COMPRESSA RIVESTITA CON FILM- USO ORALE- FLACONE (HDPE)- 30 COMPRESSE, CABOMETYX - 40 MG- COMPRESSA RIVESTITA CON FILM- USO ORALE- FLACONE (HDPE)- 30 COMPRESSE, CABOMETYX - 60 MG- COMPRESSA RIVESTITA CON FILM- USO ORALE- FLACONE (HDPE)- 30 COMPRESSE
ALMA MATER STUDIORUM UNIVERSITà DI BOLOGNA, IPSEN S.P.A.
Advanced RET-rearranged non-small cell lung cancer Carcinoma polmonare non a piccole cellule avanzato RET-riarrangiato, Pretreated and advanced stage non-small cell lung cancer with rearranged RET Carcinoma polmonare non a piccole cellule pretrattato e in stadio avanzato con RET riarrangiato, Diseases [C] - Cancer [C04]
 
 
2017-000580-32: Cabozantinib plus Ddurvalumab in patients with advanced and chemotherapy-treated bladder carcinoma, of urothelial and non-urothelial histology: an open-label, single-centre, phase 2, single-arm trial Studio di fase 2, in aperto, monocentrico, a singolo braccio con cabozantinib più durvalumab in pazienti affetti da carcinoma vescicale con istologia urotreliale e non uroteliale in fase avanzata precedentemente trattati con chemioterapia

Not yet recruiting
2
122
Europe
CABOMETYX, Durvalumab, [CABOMETYX], [Durvalumab], Film-coated tablet, Lyophilisate for solution for injection, CABOMETYX, Imfinzi
FONDAZIONE IRCCS "ISTITUTO NAZIONALE DEI TUMORI", IPSEN S.p.A., AstraZeneca S.p.A.
Patients with metastatic urothelial carcinoma who have relapsed after =1 chemotherapy regimen Pazienti con carcinoma uroteliale metastatico che sono ricaduti dopo almeno una linea di chemioterapia, Patients with metastatic urothelial carcinoma Pazienti con carcinoma uroteliale metastatico, Diseases [C] - Cancer [C04]
 
 
2018-001802-27: A Multicenter Study to investigate the Efficacy and Safety of Cabozantinib in Advanced Adrenocortical Carcinoma. Eine multizentrische Studie zur Untersuchung von Sicherheit, Verträglichkeit sowie Wirksamkeit von Cabozantinib bei Patienten mit fortgeschrittenem Nebennierenrindenkarzinom.

Not yet recruiting
2
37
Europe
Cabozantinib, Tablet, Cabometyx
University Hospital Wuerzburg, Ipsen Pharma GmbH
Advanced (Unresectable or Metastatic) Adrenocortical Carcinoma fortgeschrittenes (nicht resektables oder metastasiertes Nebennierenrindenkarzinom, Cancer of the adrenal gland that cannot be removed by surgery or has spread to distant sites Nebennierenkarzinom, welches nicht operativ entfernt werden kann oder von dem Absiedelungen (Metastasen) an anderen Stellen im Körper bestehen., Diseases [C] - Cancer [C04]
 
 
2019-000678-41: Study of cabozantinib in renal cell carcinoma with brain metastases Etude évaluant le cabozantinib dans le traitement du carcinome à cellules rénales métastatique avec métastases cérébrales

Ongoing
2
77
Europe
Coated tablet, Cabozantinib
Centre Léon Bérard, Ipsen Pharma
Metastatic renal cell carcinoma with non locally pre-treated brain metastases, in first line treatment or after one or two prior treatments. Carcinome à cellules rénales métastatique avec métastases cérébrales non prétraitées localement, en traitement de première intention ou après un ou deux traitements antérieurs., Metastatic renal cancer with brain metastases. Cancer du rein localement avancé avec des métastases cérébrales., Diseases [C] - Cancer [C04]
 
 
2017-001963-19: Cabozantinib in patients with advanced penile squamous cell carcinoma (PSCC): an open-label, single-center, phase 2, single-arm trial (CaboPen) Cabozantinib in pazienti affetti da neoplasia spinocellulare del pene avanzata (PSCC): studio monocentrico, a singolo braccio, in aperto, di fase 2 (CaboPen)

Not yet recruiting
2
37
Europe
CABOMETYX, [CABOMETYX], Film-coated tablet, CABOMETYX
FONDAZIONE IRCCS "ISTITUTO NAZIONALE DEI TUMORI", IPSEN S.p.A.
Patients with advanced penile squamous cell carcinoma (PSCC) Pazienti affetti da neoplasia spinocellulare del pene avanzata (PSCC)., Patients with advanced penile squamous cell carcinoma (PSCC). Pazienti affetti da neoplasia spinocellulare del pene avanzata (PSCC), Diseases [C] - Cancer [C04]
 
 
NCT02243605: Cabozantinib S-malate in Treating Patients With Relapsed Osteosarcoma or Ewing Sarcoma

Checkmark Data from CABONE trial in advanced Ewing sarcoma or osteosarcoma
Feb 2020 - Feb 2020: Data from CABONE trial in advanced Ewing sarcoma or osteosarcoma
Active, not recruiting
2
90
Europe
Cabozantinib S-malate, BMS-907351, Cabometyx, Cometriq, XL 184, XL-184, XL184, Laboratory Biomarker Analysis
National Cancer Institute (NCI)
Metastatic Ewing Sarcoma, Metastatic Osteosarcoma, Recurrent Ewing Sarcoma, Recurrent Osteosarcoma, Stage III Osteosarcoma AJCC v7, Stage IV Osteosarcoma AJCC v7, Stage IVA Osteosarcoma AJCC v7, Stage IVB Osteosarcoma AJCC v7, Unresectable Ewing Sarcoma, Unresectable Osteosarcoma
06/19
07/25
2019-000674-28: A phase II trial with cabozantinib in patients with metastatic colorectal cancer, after previous treatment (mCRC). Studio di fase II con cabozantinib in pazienti affetti da tumore del colonretto metastatico pre-trattato.

Ongoing
2
33
Europe
CABOZANTINIB, [NA], Film-coated tablet, CABOMETYX - 60 MG- COMPRESSA RIVESTITA CON FILM- USO ORALE- FLACONE (HDPE)- 30 COMPRESSE
Dipartimento di Medicina di Precisione - Università degli studi della Campania "L. Vanvitelli"
Patients with mCRC progressed after =2 lines of standard treatment Pazienti affetti da tumore del colon-retto metastatico in progressione dopo =2 linee di trattamento, pretreated metastatic colorectal cancer tumore del colon-retto metastatico, pretrattato, Diseases [C] - Cancer [C04]
 
 
2019-001494-88: Clinical trial evaluating the value of treatment with therapy specifically targeting the molecular alterations identified in the tumor of patients with advanced or metastatic cancer. Essai clinique évaluant l'intérêt d'un traitement par une thérapie ciblant spécifiquement les altérations moléculaires identifiées dans la tumeur de patient atteints d'un cancer à un stade avancé ou métastatique.

Not yet recruiting
2
100
Europe
HDM201, Ribociclib, Cabozantinib, Capsule, hard, Coated tablet, Kisqali, Cabometyx
Centre Léon Bérard, Centre Léon Bérard
all histological types of advanced / metastatic tumors with alterations molecular identified Tout type histologique de tumeur à un stade avancé ou métastatique avec une altération moléculaire identifiée, Advanced / metastatic cancers cancers à un stade avancé ou métastatique, Diseases [C] - Cancer [C04]
 
 
ABACO, NCT06171854: caBozantinib in Pre-treated pAtients With Metastatic COlorectal Cancer.

Active, not recruiting
2
33
Europe
Cabozantinib, Cabometyx
University of Campania "Luigi Vanvitelli"
Refractory Colorectal Adenocarcinoma
12/24
12/24
NCT01935934: Cabozantinib S-Malate in Treating Patients With Recurrent or Metastatic Endometrial Cancer

Checkmark ASCO 2014
May 2014 - May 2014: ASCO 2014
Completed
2
102
Canada, US
Cabozantinib S-malate, BMS-907351, Cabometyx, Cometriq, XL 184, XL-184, XL184, Laboratory Biomarker Analysis, Pharmacological Study
National Cancer Institute (NCI)
Endometrial Adenosquamous Carcinoma, Endometrial Clear Cell Adenocarcinoma, Endometrial Mixed Cell Adenocarcinoma, Endometrial Serous Adenocarcinoma, Metastatic Endometrioid Adenocarcinoma, Recurrent Uterine Corpus Cancer, Stage IV Uterine Corpus Cancer AJCC v7, Stage IVA Uterine Corpus Cancer AJCC v7, Stage IVB Uterine Corpus Cancer AJCC v7, Uterine Corpus Carcinosarcoma
09/19
10/24
2019-001316-38: A clinical trial on an individualized treatment strategy for patients with metastatic non-clear cell kidney cancer Et lægemiddelforsøg af en individualiseret behandlingsstrategi til patienter med undertypen non-clear celle nyrekræft, som har spredt sig

Not yet recruiting
2
30
Europe
Capsule, hard, Film-coated tablet, Powder for concentrate for solution for infusion, Concentrate for solution for infusion, Tafinlar, Tarceva, Keytruda, Mekinist, Alecensa, Lynparza, Kadcyla, Cabometyx, Xalkori, Ibrance, Tagrisso, Glivec, Sutent, Opdivo
Department of Oncology, Herlev University Hospital, Region Hovedstaden, Roche Denmark
Patients with metastatic non-clear cell or 100% sarcomatoid renal cell carcinoma referred for first line treatment at the Department of Oncology, Herlev University Hospital Patienter med metastatisk non-clear cell eller 100% sarkomatoid nyrekræft, som henvises med henblik på første linje behandling på onkologisk afdeling, Herlev Hospital, Patients with metastatic kidney cancer with the subtype non-clear cell or 100% sarcomatoid referred for first line treatment at the Department of Oncology, Herlev University Hospital Patienter med undertypen non-clear cell eller 100% sarkomatoid nyrekræft, som har spredt sig og henvises for at påbegynde den første medicinske kræftbehandling på onkologisk afdeling, Herlev Hospital, Diseases [C] - Cancer [C04]
 
 
2019-002860-29: Efficacy and safety of Cabozantinib in patients with hepatocellular carcinoma progressing on or intolerant to prior treatment with immune checkpoint inhibitors: A Phase II study (Immunocabo). Studio di fase II, in aperto, monocentrico, sulla efficacia e sulla sicurezza di cabozantinib in pazienti con epatocarcinoma in progressione o intolleranti a trattamento con immunoterapia (Immunocabo).

Not yet recruiting
2
46
Europe
Cabometyx, [Cabometyx], Film-coated tablet, CABOMETYX - 20 MG- COMPRESSA RIVESTITA CON FILM- USO ORALE- FLACONE (HDPE)- 30 COMPRESSE, CABOMETYX - 60 MG- COMPRESSA RIVESTITA CON FILM- USO ORALE- FLACONE (HDPE)- 30 COMPRESSE, CABOMETYX - 40 MG- COMPRESSA RIVESTITA CON FILM- USO ORALE- FLACONE (HDPE)- 30 COMPRESSE
IRCCS ISTITUTO CLINICO HUMANITAS, Ipsen SpA
Hepatocellular carcinoma (HCC) Carcinona epatocellulare (HCC), Hepatocellular carcinoma (HCC) Carcinona epatocellulare (HCC), Diseases [C] - Cancer [C04]
 
 
2019-004991-20: Cabozantinib trial in patients with liver cancer intolerant to Sorafenib or other treatment. (ACTION trial). Ensayo Cabozantinib en pacientes con cancer de hígado intolerantes a Sorafenib u otro tratamiento. (ensayo ACTION).

Not yet recruiting
2
40
Europe
Cabozantinib, Capsule, hard, COMETRIQ
Fundació Clinic per a la Recerca Biomèdica, Ipsen
Hepatocellular carcinoma Carcinoma hepatocelular, Hepatocellular carcinoma Carcinoma hepatocelular, Diseases [C] - Cancer [C04]
 
 
2019-004728-39: Study of Cabozantinib for Patients with Hepatocellular Carcinoma (HCC) after treatment failure of, or intolerabiliy to first line treatment.

Not yet recruiting
2
45
Europe
Cabozantinib, Film-coated tablet
Frankfurter Institut für Klinische Krebsforschung IKF GmbH am Krankenhaus Nordwest, IPSEN PHARMA GmbH
Locally advanced or metastatic and/or unresectable HCC, Locally advanced or metastatic and/or unresectable HCC, Diseases [C] - Cancer [C04]
 
 
2020-000775-20: A Study, in which patients with advanced hepatocellular carcinoma (HCC) and preserved liver function are treated with a reduced starting dose ofcabozantinib, followed by an increase of dose, after treatment failure of one previous therapy Eine Phase II Studie, in der Patienten mit fortgeschrittenem Leberzellkrebs (HCC) und erhaltener Leberfunktion mit einer verringerte Anfangsdosis Cabozantinib und anschließender Dosiserhöhung behandelt werden

Not yet recruiting
2
40
Europe
Cabozantinib, L01XE26, Film-coated tablet, Cabometyx
Frankfurter Institut für Klinische Krebsforschung IKF GmbH am Krankenhaus Nordwest, IPSEN PHARMA GmbH
Advanced stage hepatocellular carcinoma (HCC) patients with preserved liver function in second line therapy, Advanced stage hepatocellular carcinoma (HCC) patients with preserved liver function after treatment failure of one previous therapy, Diseases [C] - Cancer [C04]
 
 
NCT01755195: Cabozantinib for Adults With Advanced Soft Tissue Sarcoma

Completed
2
55
US
Cabozantinib, Cometriq
National Cancer Institute (NCI)
Refractory Soft Tissue Sarcomas
09/20
09/23
2019-004126-13: Cabozantinib treatment for patients with hepatocellular carcinoma (HCC) refractory to previous treatment Cabozantinib-Behandlung für Patienten mit Leberzellkarzinom, bei denen eine vorhergehende Behandlung nicht erfolgreich war

Not yet recruiting
2
40
Europe
Cabometyx, Film-coated tablet, Cabometyx
University Leipzig, Ipsen Pharma GmbH
Hepatocellular carcinoma Hepatozelluläres Karzinom, Hepatocellular carcinoma Leberzellkrebs, Diseases [C] - Cancer [C04]
 
 
PAPMET, NCT02761057: Testing Cabozantinib, Crizotinib, Savolitinib and Sunitinib in Kidney Cancer Which Has Progressed

Checkmark Data from SWOG S1500 trial compared with sunitinib in patients with metastatic papillary RCC
Feb 2021 - Feb 2021: Data from SWOG S1500 trial compared with sunitinib in patients with metastatic papillary RCC
Completed
2
152
Canada, US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Bone Scan, Bone Scintigraphy, Cabozantinib S-malate, BMS-907351, Cabometyx, Cometriq, XL 184, XL-184, XL184, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Crizotinib, Alkixen, Crizocent, MET Tyrosine Kinase Inhibitor PF-02341066, PF 02341066, PF-02341066, PF-2341066, PF02341066, Xalkori, Savolitinib, AZD 6094, AZD6094, HMPL-504, Volitinib, Sunitinib Malate, SU 011248, SU 11248, SU-011248, SU-11248, SU011248, SU11248, sunitinib, Sutent
National Cancer Institute (NCI), Canadian Cancer Trials Group
Locally Advanced Papillary Renal Cell Carcinoma, Metastatic Papillary Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v7, Stage IV Renal Cell Cancer AJCC v7, Type 1 Papillary Renal Cell Carcinoma, Type 2 Papillary Renal Cell Carcinoma, Unresectable Renal Cell Carcinoma
10/23
10/23
NCT01441947: Cabozantinib in Women With Metastatic Hormone-Receptor-Positive Breast Cancer

Checkmark Data-SABCS
Dec 2011 - Dec 2011: Data-SABCS
Active, not recruiting
2
68
US
Cabozantinib, XL184, Fulvestrant, Faslodex
Massachusetts General Hospital, Exelixis
Breast Cancer
12/20
12/23
2020-002541-41: A phase II trial of Cabozantinib medication in patients with advanced, high-grade neuroendocrine neoplasms, which are either well-differentiated neuroendocrine tumors or poor-differentiated neuroendocrine carcinoma but with a low proliferation rate. Both neuroendocrine neoplasms are insensitive against the available chemotherapy choice, making the newly investigated medication a new hope for better management of these subtypes.

Not yet recruiting
2
40
Europe
Cabometyx, Film-coated tablet
Universitätsmedizin Göttingen, Ipsen Pharma GmbH
We will include patients with NET G3 and upto four prior antitumoral treatment lines and NEC Ki67 low after failure of standard treatment with conventional chemotherapy., Patients with neuroendocrine tumor of high-grade with upto four prior antitumoral treatment lines and neuroendocrine carcinoma with low proliferation rate after failure of standard treatment., Diseases [C] - Cancer [C04]
 
 
2021-000520-35: Multiparametric assessment of bone response in mCRPC patients treated with Cabozantinib upon progression to chemotherapy and next generation hormonal agents VALUTAZIONE MULTIPARAMETRICA DELLA RISPOSTA OSSEA A CABOZANTINIB IN PAZIENTI CON METASTASI OSSEE DA CARCINOMA PROSTATICO RESISTENTE ALLA CASTRAZIONE IN PROGRESSIONE ALLA CHEMIOTERAPIA E ALLA TERAPIA ORMONALE DI NUOVA GENERAZIONE

Not yet recruiting
2
30
Europe
CABOMETYX, [CABOMETYX], Film-coated tablet, CABOMETYX - 20 MG- COMPRESSA RIVESTITA CON FILM- USO ORALE- FLACONE (HDPE)- 30 COMPRESSE
AZIENDA SOCIO SANITARIA TERRITORIALE DEGLI SPEDALI CIVILI DI BRESCIA, IPSEN S.P.A.
PATIENTS WITH BONE METASTASIS FROM PROSTATIC CARCINOMA PAZIENTI CON METASTASI OSSEE DA CARCINOMA PROSTATICO, PATIENTS WITH BONE METASTASIS FROM PROSTATIC CARCINOMA PAZIENTI CON METASTASI OSSEE DA CARCINOMA PROSTATICO, Diseases [C] - Cancer [C04]
 
 
NCT06482086: Efficacy of Organoid-Based Drug Screening to Guide Treatment for Locally Advanced Thyroid Cancer

Recruiting
2
75
RoW
Anlotinib, Lenvatinib, Sorafenib, Donafenib, Everolimus, Apatinib, Dabrafenib + Trametinib, Cabozantinib, Vandetanib, Entrectinib, Pralsetinib, Larotrectinib
West China Hospital
Locally Advanced Thyroid Gland Carcinoma
12/24
12/25
ADVL1622, NCT02867592 / 2019-001238-32: Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors

Active, not recruiting
2
109
US
Cabozantinib, Cabozantinib S-malate, BMS-907351, Cabometyx, Cometriq, XL 184, XL-184, XL184, Pharmacological Study
National Cancer Institute (NCI)
Adrenal Cortical Carcinoma, Alveolar Soft Part Sarcoma, Central Nervous System Neoplasm, Childhood Clear Cell Sarcoma of Soft Tissue, Clear Cell Sarcoma of Soft Tissue, Ewing Sarcoma, Hepatoblastoma, Hepatocellular Carcinoma, Osteosarcoma, Recurrent Adrenal Cortical Carcinoma, Recurrent Alveolar Soft Part Sarcoma, Recurrent Clear Cell Sarcoma of Soft Tissue, Recurrent Ewing Sarcoma, Recurrent Hepatoblastoma, Recurrent Hepatocellular Carcinoma, Recurrent Kidney Wilms Tumor, Recurrent Malignant Solid Neoplasm, Recurrent Osteosarcoma, Recurrent Primary Malignant Central Nervous System Neoplasm, Recurrent Renal Cell Carcinoma, Recurrent Rhabdomyosarcoma, Recurrent Soft Tissue Sarcoma, Recurrent Thyroid Gland Medullary Carcinoma, Refractory Adrenal Cortical Carcinoma, Refractory Alveolar Soft Part Sarcoma, Refractory Clear Cell Sarcoma of Soft Tissue, Refractory Ewing Sarcoma, Refractory Hepatoblastoma, Refractory Hepatocellular Carcinoma, Refractory Malignant Solid Neoplasm, Refractory Osteosarcoma, Refractory Primary Central Nervous System Neoplasm, Refractory Primary Malignant Central Nervous System Neoplasm, Refractory Renal Cell Carcinoma, Refractory Rhabdomyosarcoma, Refractory Soft Tissue Sarcoma, Refractory Thyroid Gland Medullary Carcinoma, Refractory Wilms Tumor, Renal Cell Carcinoma, Rhabdomyosarcoma, Soft Tissue Sarcoma, Solid Neoplasm, Thyroid Gland Medullary Carcinoma, Wilms Tumor
06/21
06/25
NCT01466036: Cabozantinib in Advanced Pancreatic Neuroendocrine and Carcinoid Tumors

Checkmark ASCO 2014
May 2014 - May 2014: ASCO 2014
Completed
2
61
US
Cabozantinib, XL184
Dana-Farber Cancer Institute
Carcinoid Tumor, Pancreatic Neuroendocrine Tumor
08/21
12/23
2021-000986-34: Cabozantinib in combination with Avelumab in patients refractory to standard chemotherapy with advanced neuroendocrine neoplasias G3 (NEN G3). Cabozantinib in Kombination mit Avelumab bei Patienten mit fortgeschrittenen neuroendokrinen Neoplasien G3 (NEN G3), welche refraktär auf eine Standard-Chemotherapie sind.

Not yet recruiting
2
30
Europe
Avelumab, Cabozantinib, MSB0010718C, Concentrate for solution for infusion, Film-coated tablet, Bavencio 20 mg/ml Konzentrat, Cabometyx 20 mg Filmtabletten, Cabometyx 40 mg Filmtabletten
University Medical Center of the Johannes Gutenberg-University Mainz, Ipsen Pharma GmbH, Merck KGaA
Advanced neuroendocrine neoplasias G3 (NEN G3) (excluding SCLC and Merkel cell carcinomas) Fortgeschrittene neuroendokrine Neoplasien G3 (NEN G3) (ausgenommen SCLC und Merkelzellkarzinome), neuroendocrine cancer neuroendokriner Krebs, Diseases [C] - Cancer [C04]
 
 
2020-002366-13: Combination of pembrolizumab and cabozantinib in patients with advanced sarcomas Association du Pembrolizumab et du Cabozantinib chez les patients porteurs d’un sarcome avancé

Not yet recruiting
2
119
Europe
PEMBROLIZUMAB, CABOZANTINIB, MK-3475, XL184, Solution for infusion, Film-coated tablet, KEYTRUDA, CABOMETYX
Institut Bergonié, Groupement Interrégional de Recherche Clinique et d’Innovation Sud-ouest Outre-mer Hospitalier, IPSEN PHARMA
Advanced /metastatic sarcomas: undifferentiated pleomorphic sarcoma, osteosarcoma and Ewing sarcoma Sarcomes localement avancés et/ou métastatiques : sarcomes indifférenciés, ostéosarcomes et sarcomes d’Ewing, Advanced /metastatic sarcomas: undifferentiated pleomorphic sarcoma, osteosarcoma and Ewing sarcoma Sarcomes localement avancés et/ou métastatiques : sarcomes indifférenciés, ostéosarcomes et sarcomes d’Ewing, Diseases [C] - Cancer [C04]
 
 
2021-005549-34: Cabo-POLARIS. Etude de phase 2 prospective multicentrique en ouvert pour évaluer la durée de traitement par cabozantinib chez les patients atteints de carcinome rénal métastatique ou localement avancé en hémodialyse (HD).

Not yet recruiting
2
24
Europe
Cabometyx, Buccal tablet, Cabozantinib (Cabometyx)
CHU Besançon, CHU Besançon, IPSEN
carcinome à cellules rénales avancé ou métastatique., cancer du rein avancé ou métastatique, Diseases [C] - Cancer [C04]
 
 
NF105-CABO, NCT02101736: Cabozantinib for Plexiform Neurofibromas (PN) in Subjects With NF1 in Children and Adults

Completed
2
45
US
Cabozantinib, XL184, Cometriq
University of Alabama at Birmingham
NF1, Neurofibromatosis, Plexiform Neurofibromas
02/22
02/22
NCT01979393 / 2013-000762-11: IRCI Gynae Sarcomas, High Grade Uterine Sarcoma

Active, not recruiting
2
58
Europe
Cabozantinib, Placebo
European Organisation for Research and Treatment of Cancer - EORTC, Gynecologic Oncology Group, NHS Greater Glasgow and Clyde
Uterine Sarcoma
03/22
05/24
2019-001075-36: Study to evaluate the safety, tolerability and efficacy of Cabozantinib in patients with hepatocellular carcinoma and impaired liver function. Studie zur Evaluierung der Sicherheit, Verträglichkeit und Wirksamkeit von Cabozantinib in Patienten mit Leberkarzinom und eingeschränkter Leberfunktion.

Not yet recruiting
2
20
Europe
Film-coated tablet, Cabometyx 20 mg Filmtabletten, Cabometyx 40 mg Filmtabletten
Universitätsmedizin Mainz, Ipsen Pharma GmbH
Hepatocellular carcinoma (HCC) Hepatozelluläres Karzinom (HCC), Liver carcinoma Leberkarzinom, Diseases [C] - Cancer [C04]
 
 
2022-000391-19: Study on Cabozantinib in subjects with recurrent or progressive glioblastoma with c-MET hyperexpression Studio su Cabozantinib in pazienti affetti da glioblastoma ricorrente o in progressione con iperespressione di c-MET

Not yet recruiting
2
40
Europe
Cabozantinib, [Cabozantinib], Film-coated tablet, CABOMETYX - 40 MG- COMPRESSA RIVESTITA CON FILM- USO ORALE- FLACONE (HDPE)- 30 COMPRESSE, CABOMETYX - 60 MG- COMPRESSA RIVESTITA CON FILM- USO ORALE- FLACONE (HDPE)- 30 COMPRESSE, CABOMETYX - 20 MG- COMPRESSA RIVESTITA CON FILM- USO ORALE- FLACONE (HDPE)- 30 COMPRESSE
AZIENDA OSPEDALIERA "S. MARIA", IPSEN SPA
recurrent or progressive glioblastoma with c-MET hyperexpression glioblastoma ricorrente o in progressione con iperespressione di c-MET, recurrent or progressive glioblastoma after standard treatment, characterized by hyperexpression of c-MET glioblastoma ricorrente o in progressione dopo terapia standard, caratterizzato da iperespressione di c-MET, Diseases [C] - Cancer [C04]
 
 
NCT02041260: A Phase II Trial of Cabozantinib for the Treatment of Radioiodine (RAI)-Refractory Differentiated Thyroid Carcinoma (DTC) in the First-line Setting

Checkmark For 1L treatment of metastatic radioiodine-refractory differentiated thyroid carcinoma
Feb 2018 - Feb 2018: For 1L treatment of metastatic radioiodine-refractory differentiated thyroid carcinoma
Active, not recruiting
2
43
US
Cabozantinib
Thomas Jefferson University
Differentiated Thyroid Cancer (DTC), Poorly Differentiated Thyroid Cancer
05/22
05/22
NCT03468985: Nivolumab, Cabozantinib S-Malate, and Ipilimumab in Treating Patients With Recurrent Stage IV Non-small Cell Lung Cancer

Completed
2
3
US
Cabozantinib, Cabozantinib s-malate, XL-184, EXEL-7184, EXEL-02977184, Cabometyx®, Ipilimumab, Anti-CTLA-4 monoclonal antibody, MDX-010, Yervoy, Nivolumab, BMS-936558, MDX1106
National Cancer Institute (NCI)
Metastatic Lung Non-Squamous Non-Small Cell Carcinoma, Recurrent Lung Non-Squamous Non-Small Cell Carcinoma, Stage IV Lung Non-Small Cell Cancer AJCC v7
05/22
12/22
CaboPen, NCT03943602: Cabozantinib in Patients With Advanced Penile Squamous Cell Carcinoma (PSCC)

Recruiting
2
37
Europe
Cabozantinib, CABOMETYX
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Penile Squamous Cell Carcinoma
06/22
09/22
2021-000027-12: Immunological variables associated to ICI toxicity in cancer patients

Not yet recruiting
2
441
Europe
atezolizumab, avelumab, cisplatin, axitinib, bevacizumab, cabozantinib, carboplatin, cemiplimab, durvalumab, etoposide, 5-Fluorouracil, ipilimumab, nab-paclitaxel, nivolumab, oxaliplatin, paclitaxel, pembrolizumab, pemetrexed, Concentrate for solution for infusion, Film-coated tablet, Concentrate for solution for injection, Concentrate and solvent for solution for infusion, Solution for injection/infusion, Powder for suspension for injection, Concentrate for concentrate for solution for infusion
Institut Jules Bordet, Les amis de Bordet, Fondation Lambeau-Marteaux,, FNRS Télévie
solid tumour, solid tumour, Diseases [C] - Cancer [C04]
 
 
UNICAB, NCT03685448: ANZUP - Non-clear Cell Post Immunotherapy CABozantinib

Recruiting
2
48
RoW
Cabozantinib, Cabometyx
Australian and New Zealand Urogenital and Prostate Cancer Trials Group
Renal Cell Carcinoma, Papillary Renal Cell Carcinoma Type 1, Papillary Renal Cell Carcinoma Type 2, Chromophobe Renal Cell Carcinoma, Sarcomatoid Renal Cell Carcinoma, Xp11.2 Translocation-Related Renal Cell Carcinoma
10/22
04/24
NCT05007613: Second-line Cabozantinib and Atezolizumab in Patients With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma

Completed
2
24
RoW
Cabozantinib 40 MG, Cabometyx, Atezolizumab Injection, Tecentriq
National Taiwan University Hospital, Ipsen, Roche Pharma AG
Esophageal Cancer, Metastatic Cancer, Squamous Cell Carcinoma
07/24
12/24
CABOCOL, NCT04205799 / 2019-002184-97: Cabozantinib for Advanced or Metastatic Cervical Carcinoma After Platinum Treatment Failure

Completed
2
57
Europe
Cabozantinib
Centre Francois Baclesse
Advanced/Metastatic Cervical Cancer
01/23
01/23
ARCADIA, NCT03824691: hARnessing CAbozantinib and Durvalumab Immuno-oncology Association: Study"

Recruiting
2
122
Europe
Cabozantinib, CABOMETYX, Durvalumab, Imfinzi
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Bladder Carcinoma
02/23
02/23
ACTION, NCT04316182 / 2014-001333-88: Cabozantinib in Patients With Hepatocellular Carcinoma

Completed
2
24
Europe
Cabozantinib, Cabometix
Fundacion Clinic per a la Recerca Biomédica, Apices Soluciones S.L.
Hepatocellular Carcinoma
02/23
02/23
NCT04714697: Cabozantinib as Subsequent Therapy to an Immune Checkpoint Based Therapy in Renal Cell Carcinoma

Not yet recruiting
2
201
RoW
Cabometyx
Asan Medical Center, Ipsen
Renal Cell Cancer
02/23
02/25
NCT04091750: Nivolumab/Ipilimumab Plus Cabozantinib in Patients With Unresectable Advanced Melanoma

Active, not recruiting
2
14
US
Nivolumab, Opdivo, Ipilimumab, Yervoy, Cabozantinib, Cabometyx
Georgetown University, MedStar Franklin Square Medical Center, Hackensack Meridian Health, Exelixis
Melanoma
08/23
12/25
2022-002419-48: Biomarker Phase II Study Of Cabozantinib In Advanced Radioactive-Iodine Refractory Differentiated Thyroid Cancer. Estudio de fase II con biomarcadores de cabozantinib en cáncer de tiroides diferenciado avanzado refractario al yodo radiactivo.

Not yet recruiting
2
41
Europe
Capsule, CABOMETYX
Grupo Español de Tumores Neuroendocrinos y Endocrinos (GETNE), IPSEN
Patients with radioiodine-refractory differentiated thyroid cancer (DTC). Pacientes con cáncer diferenciado de tiroides (DTC) refractario al yodo radioactivo., Patients thyroids cancer Pacientes con cáncer de tiroides, Diseases [C] - Cancer [C04]
 
 
NCT05039736: A Phase II Study to Evaluate the Effects of Sequential Therapy With the Anti c-MET/VEGFR Tyrosine Kinase Inhibitor (TKI), Cabozantinib, Followed by an Anti-PD-1 Antibody (Nivolumab) in Patients With Advanced HCC Who Progressed on First-line Therapy

Withdrawn
2
30
NA
Cabozantinib, XL-184, XL184, Nivolumab, BMS-936558, Opdivo
M.D. Anderson Cancer Center, Exelixis
Hepatocellular Carcinoma, Liver Cancer
05/23
05/23
CaboPoint, NCT03945773 / 2018-002820-18: Study of Cabozantinib as 2nd Line Treatment in Subjects With Locally Advanced or Metastatic Renal Cell Carcinoma (RCC) With a Clear-Cell Component Who Progressed After 1st Line Treatment With Checkpoint Inhibitors

Active, not recruiting
2
127
Europe
Cabozantinib, Cabometyx
Ipsen
Locally Advanced or Metastatic Renal Cell Carcinoma
05/23
12/30
NCT04164979: Ph II Study of Cabozantinib With Pembrolizumab in Metastatic Gastric and Gastroesophageal Adenocarcinoma

Active, not recruiting
2
20
US
Cabozantinib, CABOMETYX, COMETRIQ, Pembrolizumab, KEYTRUDA
University of California, Irvine, Exelixis
Gastric Adenocarcinoma, GastroEsophageal Cancer
11/23
12/24
Immunocabo, NCT04435977 / 2019-002860-29: Efficacy and Safety of Cabozantinib in Patients With Hepatocellular Carcinoma

Recruiting
2
46
Europe
Cabozantinib 60 MG
Istituto Clinico Humanitas, Ipsen SpA
Hepatocarcinoma
06/23
09/23
CABOMAYOR, NCT04134390 / 2019-001639-30: Study of Cabozantinib Efficacy, Safety and Tolerability in Metastatic Renal Carcinoma in Aged Fragile Patients: Study

Completed
2
25
Europe
Cabozantinib
Spanish Oncology Genito-Urinary Group, Apices Soluciones S.L.
Old Age; Debility, Renal Carcinoma Metastatic
11/23
11/23
NCT03239015: Efficacy and Safety of Precision Therapy in Refractory Tumor

Recruiting
2
300
RoW
Gefitinib, Erlotinib, Afatinib, Trastuzumab, Oxazolidine, Olaparib, Everolimus, Cabozantinib, Vemurafenib, Dabrafenib, Palbociclib, PD-1/L1 inhibitor plus anti-angiogenic agent
Baodong Qin
Rare Tumor, Refractory Tumor
06/23
12/23
CaboCHILD, NCT04454762: A Study to Evaluate the Safety, Tolerability and Efficacy of Cabozantinib in Patients With Hepatocellular Carcinoma and Impaired Liver Function

Recruiting
2
20
Europe
Cabozantinib, Cabometyx
Johannes Gutenberg University Mainz, Interdisciplinary Center Clinical Trials (IZKS), University Medical Center Mainz
Hepatocellular Carcinoma
08/23
02/24
CaboTx, NCT04204850: Cabozantinib to Treat Recurrent Liver Cancer Post Transplant

Recruiting
2
20
Canada
Cabozantinib, CABOMETYX
University Health Network, Toronto, Ipsen
Hepatocellular Carcinoma, Recurrent Cancer, Liver Transplant
08/25
12/25
MERIDIAN, NCT05265988: Multiparametric Assessment of Bone Response in mCRPC Patients Treated With Cabozantinib

Completed
2
32
Europe
Cabozantinib, Cabozantinib 40/20 mg tablet
Alfredo Berruti
Carcinoma Prostate
06/24
06/24
NCT03367741: Cabozantinib S-malate and Nivolumab in Treating Patients With Advanced, Recurrent, or Metastatic Endometrial Cancer

Active, not recruiting
2
84
Canada, US
Biopsy Procedure, Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Cabozantinib S-malate, BMS-907351, Cabometyx, Cometriq, XL 184, XL-184, XL184, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Nivolumab, ABP 206, BCD-263, BMS 936558, BMS-936558, BMS936558, CMAB819, MDX 1106, MDX-1106, MDX1106, NIVO, Nivolumab Biosimilar ABP 206, Nivolumab Biosimilar BCD-263, Nivolumab Biosimilar CMAB819, ONO 4538, ONO-4538, ONO4538, Opdivo
National Cancer Institute (NCI)
Advanced Endometrial Carcinoma, Metastatic Endometrial Carcinoma, Recurrent Endometrial Carcinoma, Stage III Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8, Stage IV Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8
12/25
12/25
CABRAMET, NCT03967522: Evaluation of Cabozantinib in Metastatic Renal Cell Carcinoma (mRCC) With Brain Metastases

Completed
2
26
Europe
Cabozantinib
Centre Leon Berard
Metastatic Renal Cell Carcinoma
10/24
11/24
LOLA, NCT04427787 / 2019-004506-10: A Trial Aiming to Assess the Safety and Activity of the Combination of Cabozantinib Plus Lanreotide in GEP and NET

Recruiting
2
69
Europe
Cabozantinib, Cabometyx, Lanreotide, IPSTYL
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Metastatic Well Differentiated Neuroendocrine Neoplasm, Neuroendocrine Tumors
11/23
11/23
NCT04200443: Cabozantinib and Temozolomide for the Treatment of Unresectable or Metastatic Leiomyosarcoma or Other Soft Tissue Sarcoma

Active, not recruiting
2
72
US
Cabozantinib, Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration, Temozolomide, CCRG-81045, Imidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide, 3, 4-dihydro-3-methyl-4-oxo-, M & B 39831, M and B 39831, Methazolastone, RP-46161, SCH 52365, Temcad, Temodal, Temodar, Temomedac, TMZ
City of Hope Medical Center, National Cancer Institute (NCI)
Metastatic Leiomyosarcoma, Metastatic Soft Tissue Sarcoma, Stage III Uterine Corpus Leiomyosarcoma AJCC v8, Stage IIIA Uterine Corpus Leiomyosarcoma AJCC v8, Stage IIIB Uterine Corpus Leiomyosarcoma AJCC v8, Stage IIIC Uterine Corpus Leiomyosarcoma AJCC v8, Stage IV Uterine Corpus Leiomyosarcoma AJCC v8, Stage IVA Uterine Corpus Leiomyosarcoma AJCC v8, Stage IVB Uterine Corpus Leiomyosarcoma AJCC v8, Unresectable Leiomyosarcoma, Unresectable Soft Tissue Sarcoma
04/25
04/25
CABATEN, NCT04400474: Trial of Cabozantinib Plus Atezolizumab in Advanced and Progressive Neoplasms of the Endocrine System. The Study

Active, not recruiting
2
93
Europe
Cabozantinib 40 mg, Atezolizumab 1200 mg
Grupo Espanol de Tumores Neuroendocrinos, Ipsen, Roche Pharma AG
Neuroendocrine Tumor, Anaplastic Thyroid Cancer, Adenocarcinoma, Pheochromocytoma, Paraganglioma
12/23
03/24
CaboRISE, NCT04522908: Dose Escalation Study of Cabozantinib for Advanced HCC Patients with Preserved Liver Function

Completed
2
40
Europe
Cabozantinib Oral Tablet, CABOMETYX
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, Johann Wolfgang Goethe University Hospital, Prof. Dr. med. Trojan
Hepatocellular Carcinoma (HCC), Second Line Treatment
10/24
10/24
CANOPY, NCT05502315: Study of Cabozantinib and Nivolumab in Metastatic Castration Resistant Prostate Cancer

Recruiting
2
47
US
Cabozantinib, Cabometyx, Nivolumab, Opdivo
Rana McKay, MD, Exelixis, Bristol-Myers Squibb
Castration-resistant Prostate Cancer, Metastatic Cancer
04/26
04/27
NCT05111574: Using Nivolumab Alone or With Cabozantinib to Prevent Mucosal Melanoma Return After Surgery

Recruiting
2
99
Canada, US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Bone Scan, Bone Scintigraphy, Cabozantinib S-malate, BMS-907351, Cabometyx, Cometriq, XL 184, XL-184, XL184, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Echocardiography Test, EC, Echocardiography, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Nivolumab, ABP 206, BCD-263, BMS 936558, BMS-936558, BMS936558, CMAB819, MDX 1106, MDX-1106, MDX1106, NIVO, Nivolumab Biosimilar ABP 206, Nivolumab Biosimilar BCD-263, Nivolumab Biosimilar CMAB819, ONO 4538, ONO-4538, ONO4538, Opdivo, Placebo Administration, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, PT
National Cancer Institute (NCI)
Anal Melanoma, Bladder Melanoma, Cervical Melanoma, Esophageal Melanoma, Gallbladder Melanoma, Head and Neck Mucosal Melanoma, Mucosal Melanoma, Mucosal Melanoma of the Urinary System, Nasopharyngeal Mucosal Melanoma, Oral Cavity Mucosal Melanoma, Penile Mucosal Melanoma, Rectal Melanoma, Recurrent Mucosal Melanoma, Sinonasal Mucosal Melanoma, Urethral Melanoma, Vaginal Melanoma, Vulvar Melanoma
12/25
12/25
NCT04197310: Cabozantinib and Nivolumab for Carcinoid Tumors

Completed
2
19
US
Nivolumab, Opdivo, Cabozantinib, Cometriq, Cabometyx
Dana-Farber Cancer Institute, Bristol-Myers Squibb, Exelixis
Carcinoid Tumor, Carcinoid Tumor of GI System, Neuroendocrine Tumors
12/23
01/24
NCT03899428: Immune Checkpoint Therapy vs Target Therapy in Reducing Serum HBsAg Levels in Patients With HBsAg+ Advanced Stage HCC

Recruiting
2
30
RoW
Durvalumab, IMFINZI®, Sorafenib, Nexavar, BAY43-9006, Lenvatinib, Lenvima, E7080, Regorafenib, Stivarga, BAY73-4506, Cabozantinib, Cabometyx, XL184
Humanity & Health Medical Group Limited
Hepatocellular Carcinoma
12/25
12/25
NCT04472767: Cabozantinib Combined With Ipilimumab/Nivolumab and TACE in Patients With Hepatocellular Carcinoma

Recruiting
2
35
US
Nivolumab, OPDIVO®, Ipilimumab, YERVOY®, Cabozantinib, CABOMETYX®, COMETRIQ, Transarterial Chemoembolization, TACE
University of California, Irvine, Exelixis
Hepatocellular Carcinoma, HCC
06/26
09/27
NCT05052723: Cabozantinib and Pembrolizumab in Metastatic Pancreas

Completed
2
21
US
Cabozantinib, Pembrolizumab
Joseph Kim, Exelixis, Merck Sharp & Dohme LLC
Pancreatic Cancer
11/24
11/24
CABOTEM, NCT04893785 / 2020-001898-78: A Trial Evaluating the Activity and Safety of Combination Between Cabozantinib and Temozolomide in Lung and GEP-NENS Progressive After Everolimus, Sunitinib or PRRT

Recruiting
2
35
Europe
Cabozantinib and Temozolomide
National Cancer Institute, Naples
Lung Neuroendocrine Neoplasm, GEP Neuroendocrine Tumor
01/25
12/26
NCT03468218: Pembrolizumab & Cabozantinib in Patients With Head and Neck Squamous Cell Cancer

Checkmark Data from a study in combination with Cabometyx for recurrent or metastatic HNSCC at ASCO 2022
May 2022 - May 2022: Data from a study in combination with Cabometyx for recurrent or metastatic HNSCC at ASCO 2022
Active, not recruiting
2
36
US
Cabozantinib, Cabometyx, Cometriq, Pembrolizumab, Keytruda, Lambrolizumab, MK-3475, SCH 900475
Emory University, Exelixis, National Institutes of Health (NIH), National Cancer Institute (NCI)
Metastatic Head and Neck Carcinoma, Paranasal Sinus Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma, Recurrent Hypopharyngeal Squamous Cell Carcinoma, Recurrent Laryngeal Squamous Cell Carcinoma, Recurrent Oral Cavity Squamous Cell Carcinoma, Recurrent Oropharyngeal Squamous Cell Carcinoma, Stage IV Hypopharyngeal Squamous Cell Carcinoma AJCC v7, Stage IV Laryngeal Squamous Cell Carcinoma AJCC v7, Stage IV Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7, Stage IV Oropharyngeal Squamous Cell Carcinoma AJCC v7, Stage IVA Hypopharyngeal Squamous Cell Carcinoma AJCC v7, Stage IVA Laryngeal Squamous Cell Carcinoma AJCC v7, Stage IVA Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7, Stage IVA Oropharyngeal Squamous Cell Carcinoma AJCC v7, Stage IVB Hypopharyngeal Squamous Cell Carcinoma AJCC v7, Stage IVB Laryngeal Squamous Cell Carcinoma AJCC v7, Stage IVB Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7, Stage IVB Oropharyngeal Squamous Cell Carcinoma AJCC v7, Stage IVC Hypopharyngeal Squamous Cell Carcinoma AJCC v7, Stage IVC Laryngeal Squamous Cell Carcinoma AJCC v7, Stage IVC Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7, Stage IVC Oropharyngeal Squamous Cell Carcinoma AJCC v7, Unresectable Head and Neck Squamous Cell Carcinoma
05/22
10/25
NCT03914300: Testing the Combination of Cabozantinib, Nivolumab, and Ipilimumab (CaboNivoIpi) for Advanced Differentiated Thyroid Cancer

Active, not recruiting
2
9
US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Cabozantinib S-malate, BMS-907351, Cabometyx, Cometriq, XL 184, XL-184, XL184, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Ipilimumab, Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, BMS 734016, BMS-734016, BMS734016, Ipilimumab Biosimilar CS1002, MDX 010, MDX-010, MDX-CTLA4, MDX010, Yervoy, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Nivolumab, ABP 206, BCD-263, BMS 936558, BMS-936558, BMS936558, CMAB819, MDX 1106, MDX-1106, MDX1106, NIVO, Nivolumab Biosimilar ABP 206, Nivolumab Biosimilar BCD-263, Nivolumab Biosimilar CMAB819, ONO 4538, ONO-4538, ONO4538, Opdivo
National Cancer Institute (NCI)
Differentiated Thyroid Gland Carcinoma, Follicular Variant Thyroid Gland Papillary Carcinoma, Poorly Differentiated Thyroid Gland Carcinoma, Refractory Differentiated Thyroid Gland Carcinoma, Refractory Thyroid Gland Carcinoma, Tall Cell Variant Thyroid Gland Papillary Carcinoma, Thyroid Gland Follicular Carcinoma, Thyroid Gland Oncocytic Carcinoma, Thyroid Gland Papillary Carcinoma
10/24
12/25
NCT05263050: Trial of an Alternative Cabozantinib Dosing Schedule in Metastatic Renal Cell Carcinoma and Neuroendocrine Tumors

Recruiting
2
111
US
Cabozantinib, XL184, Nivolumab, Opdivo
Fox Chase Cancer Center, Exelixis
Metastatic Renal Cell Carcinoma, Clear-cell Metastatic Renal Cell Carcinoma, Neuroendocrine Tumors, Carcinoid Tumor
02/26
02/27
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Cabometyx (cabozantinib tablet) / Exelixis
2018-003954-26: CYP3A4*22 genotype-guided dosing of TKIs in cancer patients: a new way of personalized therapy Op basis van CYP3A4*22 genotype doseren van tyrosine-kinase remmers bij patiënten met kanker: een nieuwe manier van gepersonaliseerde therapie.

Not yet recruiting
4
198
Europe
Film-coated tablet, Capsule, hard, Coated tablet, Tablet, Cabozantinib/Cabometyx, Cobimetinib/Cotellic, Dabrafenib/Tafinlar, Dasatinib/Sprycel, Erlotinib/Tarceva, Everolimus/Afinitor/Votubia, Imatinib, Lapatinib/Tyverb, Nilotinib/Tasigna, Olaparib/Lynparza, Palbociclib/Ibrance, Ponatinib/Iclusig, Regorafenib/Stivarga, Ruxolitinib/Jakavi, Sunitinib/Sutent, Pazopanib/Votrient, Cabozantinib/Cometriq, Olaparib?Lynparza, Brigatinib - Alunbrig, Encorafenib - Braftovi, Osimertinib/Tagrisso
Erasmus MC Cancer Institute, Erasmus MC
Patients diagnosed with a neoplasm and treated with a tyrosine kinase inhibitor which is mainly metabolised by CYP3A4. Patienten gediagnosticeerd met een maligniteit en behandeld met een tyrosine kinase inhibitor welke voornamelijk wordt gemetaboliseerd door CYP3A4., Patients diagnosed with cancer and treated with a TKI. Patienten gediagnosticeerd met kanker en behandeld met een TKI., Diseases [C] - Cancer [C04]
 
 
EXAMINER, NCT01896479 / 2013-003402-40: A Study of Two Different Doses of Cabozantinib (XL184) in Progressive, Metastatic Medullary Thyroid Cancer

Active, not recruiting
4
247
Europe, Canada, RoW
Cabozantinib (XL184) 140 mg, Cabozantinib (XL184) 60 mg, Placebo tablet, Placebo capsule
Exelixis
Medullary Thyroid Cancer
07/20
12/23
CABOLD, NCT06934057: Cabozantinib and Nivolumab Among Older Patients With Renal Cell Carcinoma

Not yet recruiting
4
50
Europe
Nivolumab, OPDIVO, Cabozantinib, CABOMETYX
Gustave Roussy, Cancer Campus, Grand Paris, Ipsen
Kidney Cancer, Renal Cell Cancer
04/28
04/28
CheckMate 9ER, NCT03141177 / 2017-000759-20: A Study of Nivolumab Combined With Cabozantinib Compared to Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma

Hourglass Jun 2023 - Jun 2023 : 3 year quality-of-life follow-up data from CheckMate -9ER trial in 1L RCC at ASCO 2023
Checkmark Data from CheckMate 9ER trial in combination with Cabometyx/Yervoy in 1L RCC at IKCS 2022
Jun 2022 - Jun 2022: Data from CheckMate 9ER trial in combination with Cabometyx/Yervoy in 1L RCC at IKCS 2022
Checkmark Exploratory analysis data in combination with Opdivo vs sunitinib for advanced 1L RCC based on CheckMate 9ER study at ASCO 2022
Jun 2022 - Jun 2022: Exploratory analysis data in combination with Opdivo vs sunitinib for advanced 1L RCC based on CheckMate 9ER study at ASCO 2022
More
Active, not recruiting
3
701
Europe, Japan, US, RoW
Nivolumab, Opdivo, BMS-936558, Cabozantinib, Cabometyx, Sunitinib, Sutent, Ipilimumab, Yervoy, BMS-734016
Bristol-Myers Squibb, Exelixis, Ono Pharmaceutical Co. Ltd
Renal Cell Carcinoma
02/20
04/24
COSMIC-311, NCT03690388 / 2018-001771-21: A Study of Cabozantinib Compared With Placebo in Subjects With Radioiodine-refractory Differentiated Thyroid Cancer Who Have Progressed After Prior Vascular Endothelial Growth Factor Receptor (VEGFR) -Targeted Therapy

Checkmark Approved in Brazil for the treatment of differentiated thyroid cancer based on COSMIC-311 trial
Dec 2022 - Dec 2022: Approved in Brazil for the treatment of differentiated thyroid cancer based on COSMIC-311 trial
Checkmark Results for prespecified subgroups based on baseline histology subtypes of papillary & follicular thyroid cancers based on COSMIC-311 study at ASCO 2022
May 2022 - May 2022: Results for prespecified subgroups based on baseline histology subtypes of papillary & follicular thyroid cancers based on COSMIC-311 study at ASCO 2022
Checkmark Results from prespecified subgroups who received prior lenvatinib and/or sorafenib treatment for differentiated thyroid cancer based on COSMIC-311 study at ASCO 2022
More
Active, not recruiting
3
187
Europe, Canada, US, RoW
Cabozantinib, XL184, Cabometyx®, Placebo
Exelixis, Ipsen
Differentiated Thyroid Cancer
08/20
12/24
COSMIC-312, NCT03755791 / 2018-003354-24: Study of Cabozantinib in Combination With Atezolizumab Versus Sorafenib in Subjects With Advanced HCC Who Have Not Received Previous Systemic Anticancer Therapy

Hourglass Jul 2022 - Dec 2022 : Market entry in combination with Tecentriq for 1L liver cancer (based on COSMIC-312 trial)
Checkmark Final data from COSMIC-312 trial in combination with Tecentriq for 1L HCC
Mar 2022 - Mar 2022: Final data from COSMIC-312 trial in combination with Tecentriq for 1L HCC
Not Appicable Jan 2022 - Mar 2022 : Submission for 1L HCC
Checkmark Presentation of data from COSMIC-312 trial in combination with Tecentriq for 1L HCC at ESMO Asia 2021
More
Active, not recruiting
3
837
Europe, Canada, US, RoW
Cabozantinib, XL184, Cabometyx®, Sorafenib, Nexavar®, Atezolizumab, Tecentriq®
Exelixis
Hepatocellular Carcinoma
03/21
12/24
2021-000615-23: Study comparing the standard administration of immunotherapy (IO) versus the same agent administered each three months in patients with metastatic cancer in response after 6 months of standard IO

Not yet recruiting
3
646
Europe
pembrolizumab, durvalumab, atezolizumab, avelumab, bevacizumab, pemetrexed, cabozantinib, Concentrate for solution for infusion, Powder for concentrate for solution for infusion, Film-coated tablet, OPDIVO, KEYTRUDA, IMFINZI, Tecentriq, Bavencio
UNICANCER, PHRC-K 2020, Fondation BMS
Oncologic metastatic tumour (lung cancer (K), renal cell K (except IMDC favorable-risk treated TKI / immunotherapy [IO] combination), head and neck K, bladder K, triple negative breast K, Merkel K and melanoma, or hepatocellular carcinoma) in PR or CR (except for melanoma, only patients in partial response) after 6 months of standard IO treatment (monotherapy or previously in combination with other immunotherapy or chemotherapy or continuous combination with pemetrexed or bevacizumab or TKI)., -, Diseases [C] - Cancer [C04]
 
 
COSMIC-313, NCT03937219 / 2018-004567-31: Study of Cabozantinib in Combination With Nivolumab and Ipilimumab in Patients With Previously Untreated Advanced or Metastatic Renal Cell Carcinoma

Feb 2023 - Dec 2023: Overall survival analysis data from COSMIC-313 trial in combination with opdivo and yervoy for advanced 1L RCC
Checkmark Detailed results from COSMIC-313 trial in combination with Opdivo and Yervoy for RCC
Sep 2022 - Sep 2022: Detailed results from COSMIC-313 trial in combination with Opdivo and Yervoy for RCC
Checkmark Top-line data from COSMIC-313 trial in combination with Opdivo and Yervoy for 1L RCC at ESMO 2022
Sep 2022 - Sep 2022: Top-line data from COSMIC-313 trial in combination with Opdivo and Yervoy for 1L RCC at ESMO 2022
More
Active, not recruiting
3
855
Europe, Canada, US, RoW
Cabozantinib, Cabometyx, XL184, Nivolumab, Opdivo, BMS-936558, Ipilimumab, Yervoy, BMS-734016, Cabozantinib-matched placebo
Exelixis
Renal Cell Carcinoma
01/22
06/26
CONTACT-01, NCT04471428 / 2020-000100-11: Study of Atezolizumab in Combination With Cabozantinib Versus Docetaxel in Patients With Metastatic Non-Small Cell Lung Cancer Previously Treated With an Anti-PD-L1/PD-1 Antibody and Platinum-Containing Chemotherapy

Checkmark CONTACT-01 study in combination with Tecentriq for 2L NSCLC did not meet its primary endpoint of overall survival at the final analysis
Dec 2022 - Dec 2022: CONTACT-01 study in combination with Tecentriq for 2L NSCLC did not meet its primary endpoint of overall survival at the final analysis
Completed
3
366
Europe, Japan, US, RoW
Cabozantinib, Atezolizumab, Tecentriq, Docetaxel
Hoffmann-La Roche, Exelixis
Carcinoma, Non-Small-Cell Lung
09/22
01/25
CONTACT-03, NCT04338269 / 2020-000502-29: A Study of Atezolizumab in Combination With Cabozantinib Compared to Cabozantinib Alone in Participants With Advanced Renal Cell Carcinoma After Immune Checkpoint Inhibitor Treatment

Jan 2023 - Jun 2023: Top-line data readout from CONTACT-03 trial in combination with Tecentriq for advanced or metastatic RCC
Checkmark Enrollment is complete for CONTACT-03 study in combination with Tecentriq for locally advanced/metastatic clear cell/non-clear cell (papillary or unclassified only) 1L RCC
Jan 2022 - Jan 2022: Enrollment is complete for CONTACT-03 study in combination with Tecentriq for locally advanced/metastatic clear cell/non-clear cell (papillary or unclassified only) 1L RCC
Checkmark CONTACT-03 phase 3 pivotal trial initiation in combination with Tecentriq for 2L RCC
Jul 2020 - Jul 2020: CONTACT-03 phase 3 pivotal trial initiation in combination with Tecentriq for 2L RCC
Completed
3
522
Europe, Canada, Japan, US, RoW
Atezolizumab, Tecentriq, Cabozantinib, Cabometyx
Hoffmann-La Roche, Exelixis, Chugai Pharmaceutical
Carcinoma, Renal Cell
01/23
03/25
LIBRETTO-531, NCT04211337 / 2019-001978-28: A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid Cancer

Active, not recruiting
3
291
Europe, Canada, Japan, US, RoW
Selpercatinib, LY3527723, LOXO-292, Cabozantinib, Vandetanib
Loxo Oncology, Inc., Eli Lilly and Company
Medullary Thyroid Cancer
05/23
02/26
CONTACT-2, NCT04446117 / 2020-000348-77: Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC

Hourglass Feb 2024 - Mar 2024 : FY'23 - Submission in Japan for CRPC (based on CONTACT-02 study)
Jan 2023 - Dec 2023: From CONTACT-02 trial in combination with Cabometyx for metastatic CRPC
Jan 2023 - Dec 2023: From trial in combination with Tecentriq for mCRPC
Hourglass Jan 2023 - Jun 2023 : Completion of enrollment of P3 CONTACT-02 trial in combination with Tecentriq for metastatic CRPC
Active, not recruiting
3
575
Europe, Canada, Japan, US, RoW
Cabozantinib, XL184, Cabometyx®, Atezolizumab, Tecentriq®, Abiraterone Acetate, Abiraterone, Zytiga, Enzalutamide, Xtandi, Prednisone
Exelixis, Roche-Genentech, Takeda
Metastatic Prostate Cancer, Prostate Adenocarcinoma
04/24
10/26
CARE1, NCT06364631: Pragmatic Clinical Trial

Recruiting
3
1250
Europe, RoW
Nivolumab, OPDIVO, Ipilimumab, YERVOY, Pembrolizumab, KEYTRUDA, Cabozantinib, CABOMETYX, Axitinib, INLYTA, Lenvatinib, LENVIMA
Gustave Roussy, Cancer Campus, Grand Paris, European Commission, CRIS Cancer Foundation, National Cancer Institute, France, Rennes University Hospital, University Hospital, Essen, Fundació Privada Institut d'Investigació Oncològica de Vall d'Hebron, The Netherlands Cancer Institute, Servicio Madrileño de Salud, Madrid, Spain, Hospital Universitario 12 de Octubre, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Medical University of Vienna, FAKULTNI NEMOCNICE OLOMOUC, International Kidney Cancer Coalition, Association pour la Recherche sur les Tumeurs du Rein, Resilience, PRIMAA, Queen Mary University of London
Metastatic Kidney Cancer, Metastatic Kidney Carcinoma
05/32
05/32
NCT06475989: Study of Targeted Therapy vs. Chemotherapy in Patients With Thyroid Cancer

Recruiting
3
264
US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Cabozantinib, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Dabrafenib, BRAF Inhibitor GSK2118436, GSK-2118436, GSK-2118436A, GSK2118436, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Questionnaire Administration, Trametinib, GSK 1120212, GSK-1120212, GSK1120212, JTP-74057, MEK Inhibitor GSK1120212
ECOG-ACRIN Cancer Research Group, National Cancer Institute (NCI)
Refractory Differentiated Thyroid Gland Carcinoma
09/30
09/30
PDIGREE, NCT03793166: Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The Study

Checkmark Initiated in combination with nivolumab and ipilimumab for 1L RCC
Jan 2019 - Jan 2019: Initiated in combination with nivolumab and ipilimumab for 1L RCC
Active, not recruiting
3
1175
US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Bone Scan, Bone Scintigraphy, Cabozantinib, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Ipilimumab, Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, BMS 734016, BMS-734016, BMS734016, Ipilimumab Biosimilar CS1002, MDX 010, MDX-010, MDX-CTLA4, MDX010, Yervoy, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Nivolumab, ABP 206, BCD-263, BMS 936558, BMS-936558, BMS936558, CMAB819, MDX 1106, MDX-1106, MDX1106, NIVO, Nivolumab Biosimilar ABP 206, Nivolumab Biosimilar BCD-263, Nivolumab Biosimilar CMAB819, ONO 4538, ONO-4538, ONO4538, Opdivo, Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration
National Cancer Institute (NCI)
Clear Cell Renal Cell Carcinoma, Metastatic Malignant Neoplasm in the Bone, Metastatic Malignant Neoplasm in the Lymph Nodes, Metastatic Malignant Neoplasm in the Soft Tissue, Metastatic Malignant Neoplasm in the Viscera, Rhabdoid Tumor of the Kidney, Sarcomatoid Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8
09/25
09/25
STROKER, NCT06726421: Systemic Therapy Alone or with Stereotactic Body Radiotherapy for Oligometastatic Kidney Cancer ( Study)

Recruiting
3
252
RoW
Stereotactic body radiotherapy (SBRT), Stereotactic ablative radiotherapy, axitinib ± immune checkpoint inhibitors (ICIs), lenvatinib ± ICIs, cabozantinib ± ICIs, sunitinib and pazopanib, Standard systemic therapy
Sun Yat-sen University
Renal Cell Carcinoma (Kidney Cancer), Kidney Cancer Metastatic, Renal Cell Carcinoma Metastatic
09/30
09/33
MAIN-CAV, NCT05092958: Testing the Addition of the Anti-cancer Drug, Cabozantinib, to the Usual Immunotherapy Treatment, Avelumab, in Patients With Metastatic Urothelial Cancer, Study

Active, not recruiting
3
654
Canada, US
Avelumab, Bavencio, MSB 0010718C, MSB-0010718C, MSB0010718C, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Bone Scan, Bone Scintigraphy, Cabozantinib S-malate, BMS-907351, Cabometyx, Cometriq, XL 184, XL-184, XL184, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration
National Cancer Institute (NCI)
Advanced Bladder Urothelial Carcinoma, Advanced Renal Pelvis Urothelial Carcinoma, Advanced Ureter Urothelial Carcinoma, Advanced Urethral Urothelial Carcinoma, Metastatic Bladder Urothelial Carcinoma, Metastatic Renal Pelvis Urothelial Carcinoma, Metastatic Ureter Urothelial Carcinoma, Metastatic Urethral Urothelial Carcinoma, Stage III Bladder Cancer AJCC v8, Stage III Renal Pelvis and Ureter Cancer AJCC v8, Stage III Renal Pelvis Cancer AJCC v8, Stage III Ureter Cancer AJCC v8, Stage III Urethral Cancer AJCC v8, Stage IV Bladder Cancer AJCC v8, Stage IV Renal Pelvis and Ureter Cancer AJCC v8, Stage IV Renal Pelvis Cancer AJCC v8, Stage IV Ureter Cancer AJCC v8, Stage IV Urethral Cancer AJCC v8
12/25
12/25
CABINET, NCT03375320: Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tumors

Hourglass Feb 2020 - Dec 2020 : Data from CABINET trial for advanced NET
Active, not recruiting
3
298
US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Cabozantinib S-malate, BMS-907351, Cabometyx, Cometriq, XL 184, XL-184, XL184, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Placebo Administration, Quality-of-Life Assessment, Quality of Life Assessment, X-Ray Imaging, Conventional X-Ray, Diagnostic Radiology, Medical Imaging, X-Ray, Plain film radiographs, Radiographic Imaging, Radiographic imaging procedure (procedure), Radiography, RG, Static X-Ray, X-Ray
National Cancer Institute (NCI)
Carcinoid Tumor, Functioning Pancreatic Neuroendocrine Tumor, Intermediate Grade Lung Neuroendocrine Neoplasm, Locally Advanced Digestive System Neuroendocrine Neoplasm, Locally Advanced Digestive System Neuroendocrine Tumor G1, Locally Advanced Lung Neuroendocrine Neoplasm, Locally Advanced Pancreatic Neuroendocrine Tumor, Locally Advanced Unresectable Digestive System Neuroendocrine Neoplasm, Low Grade Lung Neuroendocrine Neoplasm, Lung Neuroendocrine Tumor, Lung Neuroendocrine Tumor G2, Metastatic Digestive System Neuroendocrine Neoplasm, Metastatic Digestive System Neuroendocrine Tumor G1, Metastatic Lung Neuroendocrine Neoplasm, Metastatic Lung Neuroendocrine Tumor, Metastatic Pancreatic Neuroendocrine Neoplasm, Metastatic Pancreatic Neuroendocrine Tumor, Metastatic Thymus Neuroendocrine Neoplasm, Neuroendocrine Neoplasm, Neuroendocrine Tumor G2, Non-Functioning Pancreatic Neuroendocrine Tumor, Pancreatic Serotonin-Producing Neuroendocrine Tumor, Thymus Neuroendocrine Tumor, Unresectable Digestive System Neuroendocrine Neoplasm, Unresectable Digestive System Neuroendocrine Tumor G1, Unresectable Lung Neuroendocrine Neoplasm, Unresectable Pancreatic Neuroendocrine Neoplasm, Unresectable Thymus Neuroendocrine Neoplasm
08/23
11/25
LITESPARK-011, NCT04586231 / 2020-002075-35: A Study of Belzutifan (MK-6482) in Combination With Lenvatinib Versus Cabozantinib for Treatment of Renal Cell Carcinoma (MK-6482-011)

Active, not recruiting
3
708
Europe, Canada, Japan, US, RoW
Belzutifan, PT2977, MK-6482, WELIREG™, Lenvatinib, Lenvima, E7080, MK-7902, Cabozantinib, Cabometyx, Cometriq, XL184, BMS-907351
Merck Sharp & Dohme LLC, Eisai Inc.
Carcinoma, Renal Cell
02/26
02/27
AcceleRET-MTC, NCT04760288 / 2020-005269-15: A Study of Pralsetinib Versus Standard of Care (SOC) for Treatment of RET-Mutated Medullary Thyroid Cancer (MTC).

Withdrawn
3
198
Europe
Pralsetinib, Cabozantinib, Vandetanib
Hoffmann-La Roche
Medullary Thyroid Cancer
10/27
04/35
IMbrella B, NCT03768063 / 2018-003352-20: A Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study

Active, not recruiting
3
1000
Europe, Japan, US, RoW
Atezolizumab, Tecentriq, Bevacizumab, Avastin, Alectinib, Alecensa, Cobimetinib, Cotellic, Vemurafenib, Zelboraf, FAP IL2V, simlukafusp alfa, Venetoclax, Venclexta, Enzalutamide, Xtandi, Pembrolizumab, Keytruda, Sunitinib, Sutent, Niraparib, Zejula, Cabozantinib, Cometriq, Pemetrexed, Paclitaxel, Emactuzumab, Rucaparib
Hoffmann-La Roche, F. Hoffmann-La Roche Ltd, F. Hoffmann- La Roche Ltd
Cancer
07/28
07/28
NCT05683197: A Study to Test the Addition of the Drug Cabozantinib to Chemotherapy in Patients With Newly Diagnosed Osteosarcoma

Not yet recruiting
2/3
1122
NA
Cabozantinib S-malate, 1140909-48-3, BMS-907351, Butanedioic acid, 2-hydroxy-, (2S)-, compd. with N-[4-[(6,7-dimethoxy-4-quinolinyl)oxy]phenyl]-N'-(4-fluorophenyl)-1, 1-cyclopropanedicarboxamide (1:1), Cabometyx, Cometriq, XL-184, XL184, Methotrexate, 4-Amino-10-methylfolic Acid, 4-Amino-4-deoxy-10-methylpteroyl-L-glutamic Acid, 59-05-2, Abitrexate, Alpha-Methopterin, Amethopterin, Brimexate, CL 14377, CL-14377, Farmitrexat, Fauldexato, Folex, Folex PFS, Lantarel, Ledertrexate, Lumexon, Maxtrex, Medsatrexate, Metex, Methoblastin, Methotrexate LPF, Methylaminopterin, Methotrexatum, Metrotex, Mexate, Mexate-AQ, MTX, N-[4-[[(2,4-Diamino-6-pteridinyl)methyl]methylamino]benzoyl]-L-glutamic Acid, Novatrex, Rheumatrex, Texate, Tremetex, Trexeron, Trixilem, WR-19039, Doxorubicin Hydrochloride, 14-Hydroxydaunorubicin Hydrochloride, 25316-40-9, 3-Hydroxyacetyldaunorubicin Hydrochloride, 12-Naphthacenedione, 6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7, 10-[(3-amino-2,3,,10-tetrahydro-6, 11-trihydroxy-8-hydroxyacetyl)-1-methoxy-, hydrochloride, (8S-cis)- (9CI), Cisplatin, (SP-4-2)-Diamminedichloroplatinum, 15663-27-1, Abiplatin, Blastolem, Briplatin, CDDP, Cis-diammine-dichloroplatinum, X-Ray Imaging, Computed Tomography, Magnetic Resonance Imaging, Bone Scan
Children's Oncology Group, National Cancer Institute (NCI)
Localized Osteosarcoma, Metastatic Osteosarcoma, Resectable Osteosarcoma, Unresectable Osteosarcoma
03/30
03/30
NCT05691478: A Study to Test the Addition of the Drug Cabozantinib to Chemotherapy in Patients With Newly Diagnosed Osteosarcoma

Suspended
2/3
1122
US
Bone Scan, Bone Scintigraphy, Cabozantinib S-malate, BMS-907351, Cabometyx, Cometriq, XL 184, XL-184, XL184, Cisplatin, Abiplatin, Blastolem, Briplatin, CDDP, Cis-diammine-dichloroplatinum, Cis-diamminedichloridoplatinum, Cis-diamminedichloro Platinum (II), Cis-diamminedichloroplatinum, Cis-dichloroammine Platinum (II), Cis-platinous Diamine Dichloride, Cis-platinum, Cis-platinum II, Cis-platinum II Diamine Dichloride, Cismaplat, Cisplatina, Cisplatinum, Cisplatyl, Citoplatino, Citosin, Cysplatyna, DDP, Lederplatin, Metaplatin, Neoplatin, Peyrone's Chloride, Peyrone's Salt, Placis, Plastistil, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platinol- AQ, Platinol-AQ, Platinol-AQ VHA Plus, Platinoxan, Platinum, Platinum Diamminodichloride, Platiran, Platistin, Platosin, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Doxorubicin Hydrochloride, 5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8, 9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, hydrochloride, (8S-cis)- (9CI), ADM, Adriacin, Adriamycin, Adriamycin Hydrochloride, Adriamycin PFS, Adriamycin RDF, ADRIAMYCIN, HYDROCHLORIDE, Adriamycine, Adriblastina, Adriblastine, Adrimedac, Chloridrato de Doxorrubicina, DOX, DOXO-CELL, Doxolem, Doxorubicin HCl, Doxorubicin.HCl, Doxorubin, Farmiblastina, FI 106, FI-106, FI106, hydroxydaunorubicin, Rubex, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Methotrexate, Abitrexate, Alpha-Methopterin, Amethopterin, Brimexate, CL 14377, CL-14377, Emtexate, Emthexat, Emthexate, Farmitrexat, Fauldexato, Folex, Folex PFS, Jylamvo, Lantarel, Ledertrexate, Lumexon, Maxtrex, Medsatrexate, Metex, Methoblastin, Methotrexate LPF, Methotrexate Methylaminopterin, Methotrexatum, Metotrexato, Metrotex, Mexate, Mexate-AQ, MTX, Novatrex, Rheumatrex, Texate, Tremetex, Trexeron, Trixilem, WR-19039, Surgical Procedure, Operation, Surgery, Surgery Type, Surgery, NOS, Surgical, Surgical Intervention, Surgical Interventions, Surgical Procedures, Type of Surgery, X-Ray Imaging, Conventional X-Ray, Diagnostic Radiology, Medical Imaging, X-Ray, Plain film radiographs, Radiographic Imaging, Radiographic imaging procedure (procedure), Radiography, RG, Static X-Ray, X-Ray
National Cancer Institute (NCI)
High Grade Osteosarcoma, Localized Osteosarcoma, Metastatic Osteosarcoma, Secondary Osteosarcoma
03/30
03/30
jRCTs011210055: Cabozantinib ePRO study

Completed
2
105
Japan
Cabometyx (cabozantinib tablet) - Exelixis
Hokkaido University Hospital, Takeda Pharmaceutical Company Limited
Renal cell carcinoma
 
 
2013-000762-11: A randomized double-blind phase II study evaluating the role of maintenance therapy with cabozantinib in High Grade Uterine Sarcoma (HGUtS) after stabilization or response to doxorubicin +/- ifosfamide following surgery or in metastatic first line treatment

Ongoing
2
90
Europe, RoW
Cabozantinib, XL184, Film-coated tablet
European Organisation for Research and Treatment of Cancer (EORTC), Exelixis, European Organisation for Research and Treatment of Cancer (EORTC)
High Grade Undifferentiated Uterine Sarcoma (HGUS), Uterine Sarcoma, Diseases [C] - Cancer [C04]
 
 
NCT01815151: A Study of XL184 (Cabozantinib) in Endometrial Cancer

Not yet recruiting
2
36
Canada
XL-184, Cabozantinib
University Health Network, Toronto, National Cancer Institute (NCI)
Metastatic, Endometrial Cancer, Endometrioid, Serous, Mix Histology, Carcinosarcoma, Clear Cell, Adenosquamous
04/15
09/15
NCT01708954: Erlotinib Hydrochloride and Cabozantinib-s-Malate Alone or in Combination as Second or Third Line Therapy in Treating Patients With Stage IV Non-small Cell Lung Cancer

Checkmark Data from E1512 study in 2L or 3L EGFR wild-type NSCLC at ASCO
May 2015 - May 2015: Data from E1512 study in 2L or 3L EGFR wild-type NSCLC at ASCO
Checkmark In EGFR-wild type NSCLC
Nov 2014 - Nov 2014: In EGFR-wild type NSCLC
Checkmark From Eastern Cooperative Oncology Group trial in second line or third line EGFR wild type NSCLC
More
Active, not recruiting
2
125
US
Cabozantinib S-malate, BMS-907351, Cabometyx, Cometriq, XL 184, XL-184, XL184, Erlotinib Hydrochloride, CP 358, CP-358, Cp-358,774, CP358, OSI 774, OSI-774, OSI774, Tarceva, Laboratory Biomarker Analysis
National Cancer Institute (NCI)
Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Non-Small Cell Cancer AJCC v7
08/15
03/26
NCT02036476: Cabozantinib in Recurrent/Metastatic Merkel Cell Carcinoma

Terminated
2
8
US
Cabozantinib, XL184, Cometriq
Dana-Farber Cancer Institute, Exelixis
Merkel Cell Carcinoma, Skin Cancer
04/16
07/16
2017-003103-22: Advanced or Metastatic Collecting ducts renal cell carcinoma Cabozantinib nel carcinoma renale dei dotti collettori di Bellini.

Not yet recruiting
2
23
Europe
Film-coated tablet, CABOMETYX
FONDAZIONE IRCCS "ISTITUTO NAZIONALE DEI TUMORI", IPSEN S.p.A.
Collecting Duct Renal Cell Carcinoma Carcinoma renale dei dotti collettori di Bellini (CDC), Collecting Duct Renal Cell Carcinoma Carcinoma renale dei dotti collettori di Bellini (CDC), Diseases [C] - Cancer [C04]
 
 
2018-000682-36: cabozantinib for salivary gland cancer patients cabozantinib voor speekselklierkanker

Ongoing
2
43
Europe
Cabometyx, Tablet, Cabometyx
Radboud university medical center, Ipsen
Salivary gland cancer Speekselklierkanker, salivary gland cancer Speekselklierkanker, Diseases [C] - Cancer [C04]
 
 
2018-001201-93: Clinical trial for the evaluation of a new drug (cabozantinib) treatment given before having kidney surgery in patients with kidney cancer that is advanced or has spread Ensayo clínico para la evaluación de un nuevo tratamiento farmacológico (cabozantinib) administrado antes de una cirugía renal en pacientes con cáncer de riñón que está avanzado o se ha diseminado

Ongoing
2
50
Europe
Cabometyx, XL184, Film-coated tablet, Cabometyx
Fundación ONCOSUR, Ipsen Pharma
Locally Advanced or Metastatic Renal Cell Carcinoma Cáncer de células renales localmente avanzado o metastásico, Patients with Kidney Cancer that is advanced or that has spread. Pacientes con cáncer de riñón avanzado o que se ha extendido, Diseases [C] - Cancer [C04]
 
 
NCT06377722: Cabozantinib Treatment Prior to Cytoreductive Nephrectomy in Patients With Advanced or Metastatic Renal Cells Cancer

Terminated
2
18
Europe
Cabozantinib, No other intervention names
Fundacion Oncosur
Renal Cell Carcinoma Metastatic, Renal Cell Carcinoma Stage IV, Renal Cell Carcinoma Stage III
08/22
08/22
2018-002948-88: Phase II study with Cabozantinib in patients with RET positive NSCLC Studio di fase II con Cabozantinib in pazienti con NSCLC RET positivo

Ongoing
2
25
Europe
CABOMETYX, [NA], Tablet, CABOMETYX - 20 MG- COMPRESSA RIVESTITA CON FILM- USO ORALE- FLACONE (HDPE)- 30 COMPRESSE, CABOMETYX - 40 MG- COMPRESSA RIVESTITA CON FILM- USO ORALE- FLACONE (HDPE)- 30 COMPRESSE, CABOMETYX - 60 MG- COMPRESSA RIVESTITA CON FILM- USO ORALE- FLACONE (HDPE)- 30 COMPRESSE
ALMA MATER STUDIORUM UNIVERSITà DI BOLOGNA, IPSEN S.P.A.
Advanced RET-rearranged non-small cell lung cancer Carcinoma polmonare non a piccole cellule avanzato RET-riarrangiato, Pretreated and advanced stage non-small cell lung cancer with rearranged RET Carcinoma polmonare non a piccole cellule pretrattato e in stadio avanzato con RET riarrangiato, Diseases [C] - Cancer [C04]
 
 
2017-000580-32: Cabozantinib plus Ddurvalumab in patients with advanced and chemotherapy-treated bladder carcinoma, of urothelial and non-urothelial histology: an open-label, single-centre, phase 2, single-arm trial Studio di fase 2, in aperto, monocentrico, a singolo braccio con cabozantinib più durvalumab in pazienti affetti da carcinoma vescicale con istologia urotreliale e non uroteliale in fase avanzata precedentemente trattati con chemioterapia

Not yet recruiting
2
122
Europe
CABOMETYX, Durvalumab, [CABOMETYX], [Durvalumab], Film-coated tablet, Lyophilisate for solution for injection, CABOMETYX, Imfinzi
FONDAZIONE IRCCS "ISTITUTO NAZIONALE DEI TUMORI", IPSEN S.p.A., AstraZeneca S.p.A.
Patients with metastatic urothelial carcinoma who have relapsed after =1 chemotherapy regimen Pazienti con carcinoma uroteliale metastatico che sono ricaduti dopo almeno una linea di chemioterapia, Patients with metastatic urothelial carcinoma Pazienti con carcinoma uroteliale metastatico, Diseases [C] - Cancer [C04]
 
 
2018-001802-27: A Multicenter Study to investigate the Efficacy and Safety of Cabozantinib in Advanced Adrenocortical Carcinoma. Eine multizentrische Studie zur Untersuchung von Sicherheit, Verträglichkeit sowie Wirksamkeit von Cabozantinib bei Patienten mit fortgeschrittenem Nebennierenrindenkarzinom.

Not yet recruiting
2
37
Europe
Cabozantinib, Tablet, Cabometyx
University Hospital Wuerzburg, Ipsen Pharma GmbH
Advanced (Unresectable or Metastatic) Adrenocortical Carcinoma fortgeschrittenes (nicht resektables oder metastasiertes Nebennierenrindenkarzinom, Cancer of the adrenal gland that cannot be removed by surgery or has spread to distant sites Nebennierenkarzinom, welches nicht operativ entfernt werden kann oder von dem Absiedelungen (Metastasen) an anderen Stellen im Körper bestehen., Diseases [C] - Cancer [C04]
 
 
2019-000678-41: Study of cabozantinib in renal cell carcinoma with brain metastases Etude évaluant le cabozantinib dans le traitement du carcinome à cellules rénales métastatique avec métastases cérébrales

Ongoing
2
77
Europe
Coated tablet, Cabozantinib
Centre Léon Bérard, Ipsen Pharma
Metastatic renal cell carcinoma with non locally pre-treated brain metastases, in first line treatment or after one or two prior treatments. Carcinome à cellules rénales métastatique avec métastases cérébrales non prétraitées localement, en traitement de première intention ou après un ou deux traitements antérieurs., Metastatic renal cancer with brain metastases. Cancer du rein localement avancé avec des métastases cérébrales., Diseases [C] - Cancer [C04]
 
 
2017-001963-19: Cabozantinib in patients with advanced penile squamous cell carcinoma (PSCC): an open-label, single-center, phase 2, single-arm trial (CaboPen) Cabozantinib in pazienti affetti da neoplasia spinocellulare del pene avanzata (PSCC): studio monocentrico, a singolo braccio, in aperto, di fase 2 (CaboPen)

Not yet recruiting
2
37
Europe
CABOMETYX, [CABOMETYX], Film-coated tablet, CABOMETYX
FONDAZIONE IRCCS "ISTITUTO NAZIONALE DEI TUMORI", IPSEN S.p.A.
Patients with advanced penile squamous cell carcinoma (PSCC) Pazienti affetti da neoplasia spinocellulare del pene avanzata (PSCC)., Patients with advanced penile squamous cell carcinoma (PSCC). Pazienti affetti da neoplasia spinocellulare del pene avanzata (PSCC), Diseases [C] - Cancer [C04]
 
 
NCT02243605: Cabozantinib S-malate in Treating Patients With Relapsed Osteosarcoma or Ewing Sarcoma

Checkmark Data from CABONE trial in advanced Ewing sarcoma or osteosarcoma
Feb 2020 - Feb 2020: Data from CABONE trial in advanced Ewing sarcoma or osteosarcoma
Active, not recruiting
2
90
Europe
Cabozantinib S-malate, BMS-907351, Cabometyx, Cometriq, XL 184, XL-184, XL184, Laboratory Biomarker Analysis
National Cancer Institute (NCI)
Metastatic Ewing Sarcoma, Metastatic Osteosarcoma, Recurrent Ewing Sarcoma, Recurrent Osteosarcoma, Stage III Osteosarcoma AJCC v7, Stage IV Osteosarcoma AJCC v7, Stage IVA Osteosarcoma AJCC v7, Stage IVB Osteosarcoma AJCC v7, Unresectable Ewing Sarcoma, Unresectable Osteosarcoma
06/19
07/25
2019-000674-28: A phase II trial with cabozantinib in patients with metastatic colorectal cancer, after previous treatment (mCRC). Studio di fase II con cabozantinib in pazienti affetti da tumore del colonretto metastatico pre-trattato.

Ongoing
2
33
Europe
CABOZANTINIB, [NA], Film-coated tablet, CABOMETYX - 60 MG- COMPRESSA RIVESTITA CON FILM- USO ORALE- FLACONE (HDPE)- 30 COMPRESSE
Dipartimento di Medicina di Precisione - Università degli studi della Campania "L. Vanvitelli"
Patients with mCRC progressed after =2 lines of standard treatment Pazienti affetti da tumore del colon-retto metastatico in progressione dopo =2 linee di trattamento, pretreated metastatic colorectal cancer tumore del colon-retto metastatico, pretrattato, Diseases [C] - Cancer [C04]
 
 
2019-001494-88: Clinical trial evaluating the value of treatment with therapy specifically targeting the molecular alterations identified in the tumor of patients with advanced or metastatic cancer. Essai clinique évaluant l'intérêt d'un traitement par une thérapie ciblant spécifiquement les altérations moléculaires identifiées dans la tumeur de patient atteints d'un cancer à un stade avancé ou métastatique.

Not yet recruiting
2
100
Europe
HDM201, Ribociclib, Cabozantinib, Capsule, hard, Coated tablet, Kisqali, Cabometyx
Centre Léon Bérard, Centre Léon Bérard
all histological types of advanced / metastatic tumors with alterations molecular identified Tout type histologique de tumeur à un stade avancé ou métastatique avec une altération moléculaire identifiée, Advanced / metastatic cancers cancers à un stade avancé ou métastatique, Diseases [C] - Cancer [C04]
 
 
ABACO, NCT06171854: caBozantinib in Pre-treated pAtients With Metastatic COlorectal Cancer.

Active, not recruiting
2
33
Europe
Cabozantinib, Cabometyx
University of Campania "Luigi Vanvitelli"
Refractory Colorectal Adenocarcinoma
12/24
12/24
NCT01935934: Cabozantinib S-Malate in Treating Patients With Recurrent or Metastatic Endometrial Cancer

Checkmark ASCO 2014
May 2014 - May 2014: ASCO 2014
Completed
2
102
Canada, US
Cabozantinib S-malate, BMS-907351, Cabometyx, Cometriq, XL 184, XL-184, XL184, Laboratory Biomarker Analysis, Pharmacological Study
National Cancer Institute (NCI)
Endometrial Adenosquamous Carcinoma, Endometrial Clear Cell Adenocarcinoma, Endometrial Mixed Cell Adenocarcinoma, Endometrial Serous Adenocarcinoma, Metastatic Endometrioid Adenocarcinoma, Recurrent Uterine Corpus Cancer, Stage IV Uterine Corpus Cancer AJCC v7, Stage IVA Uterine Corpus Cancer AJCC v7, Stage IVB Uterine Corpus Cancer AJCC v7, Uterine Corpus Carcinosarcoma
09/19
10/24
2019-001316-38: A clinical trial on an individualized treatment strategy for patients with metastatic non-clear cell kidney cancer Et lægemiddelforsøg af en individualiseret behandlingsstrategi til patienter med undertypen non-clear celle nyrekræft, som har spredt sig

Not yet recruiting
2
30
Europe
Capsule, hard, Film-coated tablet, Powder for concentrate for solution for infusion, Concentrate for solution for infusion, Tafinlar, Tarceva, Keytruda, Mekinist, Alecensa, Lynparza, Kadcyla, Cabometyx, Xalkori, Ibrance, Tagrisso, Glivec, Sutent, Opdivo
Department of Oncology, Herlev University Hospital, Region Hovedstaden, Roche Denmark
Patients with metastatic non-clear cell or 100% sarcomatoid renal cell carcinoma referred for first line treatment at the Department of Oncology, Herlev University Hospital Patienter med metastatisk non-clear cell eller 100% sarkomatoid nyrekræft, som henvises med henblik på første linje behandling på onkologisk afdeling, Herlev Hospital, Patients with metastatic kidney cancer with the subtype non-clear cell or 100% sarcomatoid referred for first line treatment at the Department of Oncology, Herlev University Hospital Patienter med undertypen non-clear cell eller 100% sarkomatoid nyrekræft, som har spredt sig og henvises for at påbegynde den første medicinske kræftbehandling på onkologisk afdeling, Herlev Hospital, Diseases [C] - Cancer [C04]
 
 
2019-002860-29: Efficacy and safety of Cabozantinib in patients with hepatocellular carcinoma progressing on or intolerant to prior treatment with immune checkpoint inhibitors: A Phase II study (Immunocabo). Studio di fase II, in aperto, monocentrico, sulla efficacia e sulla sicurezza di cabozantinib in pazienti con epatocarcinoma in progressione o intolleranti a trattamento con immunoterapia (Immunocabo).

Not yet recruiting
2
46
Europe
Cabometyx, [Cabometyx], Film-coated tablet, CABOMETYX - 20 MG- COMPRESSA RIVESTITA CON FILM- USO ORALE- FLACONE (HDPE)- 30 COMPRESSE, CABOMETYX - 60 MG- COMPRESSA RIVESTITA CON FILM- USO ORALE- FLACONE (HDPE)- 30 COMPRESSE, CABOMETYX - 40 MG- COMPRESSA RIVESTITA CON FILM- USO ORALE- FLACONE (HDPE)- 30 COMPRESSE
IRCCS ISTITUTO CLINICO HUMANITAS, Ipsen SpA
Hepatocellular carcinoma (HCC) Carcinona epatocellulare (HCC), Hepatocellular carcinoma (HCC) Carcinona epatocellulare (HCC), Diseases [C] - Cancer [C04]
 
 
2019-004991-20: Cabozantinib trial in patients with liver cancer intolerant to Sorafenib or other treatment. (ACTION trial). Ensayo Cabozantinib en pacientes con cancer de hígado intolerantes a Sorafenib u otro tratamiento. (ensayo ACTION).

Not yet recruiting
2
40
Europe
Cabozantinib, Capsule, hard, COMETRIQ
Fundació Clinic per a la Recerca Biomèdica, Ipsen
Hepatocellular carcinoma Carcinoma hepatocelular, Hepatocellular carcinoma Carcinoma hepatocelular, Diseases [C] - Cancer [C04]
 
 
2019-004728-39: Study of Cabozantinib for Patients with Hepatocellular Carcinoma (HCC) after treatment failure of, or intolerabiliy to first line treatment.

Not yet recruiting
2
45
Europe
Cabozantinib, Film-coated tablet
Frankfurter Institut für Klinische Krebsforschung IKF GmbH am Krankenhaus Nordwest, IPSEN PHARMA GmbH
Locally advanced or metastatic and/or unresectable HCC, Locally advanced or metastatic and/or unresectable HCC, Diseases [C] - Cancer [C04]
 
 
2020-000775-20: A Study, in which patients with advanced hepatocellular carcinoma (HCC) and preserved liver function are treated with a reduced starting dose ofcabozantinib, followed by an increase of dose, after treatment failure of one previous therapy Eine Phase II Studie, in der Patienten mit fortgeschrittenem Leberzellkrebs (HCC) und erhaltener Leberfunktion mit einer verringerte Anfangsdosis Cabozantinib und anschließender Dosiserhöhung behandelt werden

Not yet recruiting
2
40
Europe
Cabozantinib, L01XE26, Film-coated tablet, Cabometyx
Frankfurter Institut für Klinische Krebsforschung IKF GmbH am Krankenhaus Nordwest, IPSEN PHARMA GmbH
Advanced stage hepatocellular carcinoma (HCC) patients with preserved liver function in second line therapy, Advanced stage hepatocellular carcinoma (HCC) patients with preserved liver function after treatment failure of one previous therapy, Diseases [C] - Cancer [C04]
 
 
NCT01755195: Cabozantinib for Adults With Advanced Soft Tissue Sarcoma

Completed
2
55
US
Cabozantinib, Cometriq
National Cancer Institute (NCI)
Refractory Soft Tissue Sarcomas
09/20
09/23
2019-004126-13: Cabozantinib treatment for patients with hepatocellular carcinoma (HCC) refractory to previous treatment Cabozantinib-Behandlung für Patienten mit Leberzellkarzinom, bei denen eine vorhergehende Behandlung nicht erfolgreich war

Not yet recruiting
2
40
Europe
Cabometyx, Film-coated tablet, Cabometyx
University Leipzig, Ipsen Pharma GmbH
Hepatocellular carcinoma Hepatozelluläres Karzinom, Hepatocellular carcinoma Leberzellkrebs, Diseases [C] - Cancer [C04]
 
 
PAPMET, NCT02761057: Testing Cabozantinib, Crizotinib, Savolitinib and Sunitinib in Kidney Cancer Which Has Progressed

Checkmark Data from SWOG S1500 trial compared with sunitinib in patients with metastatic papillary RCC
Feb 2021 - Feb 2021: Data from SWOG S1500 trial compared with sunitinib in patients with metastatic papillary RCC
Completed
2
152
Canada, US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Bone Scan, Bone Scintigraphy, Cabozantinib S-malate, BMS-907351, Cabometyx, Cometriq, XL 184, XL-184, XL184, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Crizotinib, Alkixen, Crizocent, MET Tyrosine Kinase Inhibitor PF-02341066, PF 02341066, PF-02341066, PF-2341066, PF02341066, Xalkori, Savolitinib, AZD 6094, AZD6094, HMPL-504, Volitinib, Sunitinib Malate, SU 011248, SU 11248, SU-011248, SU-11248, SU011248, SU11248, sunitinib, Sutent
National Cancer Institute (NCI), Canadian Cancer Trials Group
Locally Advanced Papillary Renal Cell Carcinoma, Metastatic Papillary Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v7, Stage IV Renal Cell Cancer AJCC v7, Type 1 Papillary Renal Cell Carcinoma, Type 2 Papillary Renal Cell Carcinoma, Unresectable Renal Cell Carcinoma
10/23
10/23
NCT01441947: Cabozantinib in Women With Metastatic Hormone-Receptor-Positive Breast Cancer

Checkmark Data-SABCS
Dec 2011 - Dec 2011: Data-SABCS
Active, not recruiting
2
68
US
Cabozantinib, XL184, Fulvestrant, Faslodex
Massachusetts General Hospital, Exelixis
Breast Cancer
12/20
12/23
2020-002541-41: A phase II trial of Cabozantinib medication in patients with advanced, high-grade neuroendocrine neoplasms, which are either well-differentiated neuroendocrine tumors or poor-differentiated neuroendocrine carcinoma but with a low proliferation rate. Both neuroendocrine neoplasms are insensitive against the available chemotherapy choice, making the newly investigated medication a new hope for better management of these subtypes.

Not yet recruiting
2
40
Europe
Cabometyx, Film-coated tablet
Universitätsmedizin Göttingen, Ipsen Pharma GmbH
We will include patients with NET G3 and upto four prior antitumoral treatment lines and NEC Ki67 low after failure of standard treatment with conventional chemotherapy., Patients with neuroendocrine tumor of high-grade with upto four prior antitumoral treatment lines and neuroendocrine carcinoma with low proliferation rate after failure of standard treatment., Diseases [C] - Cancer [C04]
 
 
2021-000520-35: Multiparametric assessment of bone response in mCRPC patients treated with Cabozantinib upon progression to chemotherapy and next generation hormonal agents VALUTAZIONE MULTIPARAMETRICA DELLA RISPOSTA OSSEA A CABOZANTINIB IN PAZIENTI CON METASTASI OSSEE DA CARCINOMA PROSTATICO RESISTENTE ALLA CASTRAZIONE IN PROGRESSIONE ALLA CHEMIOTERAPIA E ALLA TERAPIA ORMONALE DI NUOVA GENERAZIONE

Not yet recruiting
2
30
Europe
CABOMETYX, [CABOMETYX], Film-coated tablet, CABOMETYX - 20 MG- COMPRESSA RIVESTITA CON FILM- USO ORALE- FLACONE (HDPE)- 30 COMPRESSE
AZIENDA SOCIO SANITARIA TERRITORIALE DEGLI SPEDALI CIVILI DI BRESCIA, IPSEN S.P.A.
PATIENTS WITH BONE METASTASIS FROM PROSTATIC CARCINOMA PAZIENTI CON METASTASI OSSEE DA CARCINOMA PROSTATICO, PATIENTS WITH BONE METASTASIS FROM PROSTATIC CARCINOMA PAZIENTI CON METASTASI OSSEE DA CARCINOMA PROSTATICO, Diseases [C] - Cancer [C04]
 
 
NCT06482086: Efficacy of Organoid-Based Drug Screening to Guide Treatment for Locally Advanced Thyroid Cancer

Recruiting
2
75
RoW
Anlotinib, Lenvatinib, Sorafenib, Donafenib, Everolimus, Apatinib, Dabrafenib + Trametinib, Cabozantinib, Vandetanib, Entrectinib, Pralsetinib, Larotrectinib
West China Hospital
Locally Advanced Thyroid Gland Carcinoma
12/24
12/25
ADVL1622, NCT02867592 / 2019-001238-32: Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors

Active, not recruiting
2
109
US
Cabozantinib, Cabozantinib S-malate, BMS-907351, Cabometyx, Cometriq, XL 184, XL-184, XL184, Pharmacological Study
National Cancer Institute (NCI)
Adrenal Cortical Carcinoma, Alveolar Soft Part Sarcoma, Central Nervous System Neoplasm, Childhood Clear Cell Sarcoma of Soft Tissue, Clear Cell Sarcoma of Soft Tissue, Ewing Sarcoma, Hepatoblastoma, Hepatocellular Carcinoma, Osteosarcoma, Recurrent Adrenal Cortical Carcinoma, Recurrent Alveolar Soft Part Sarcoma, Recurrent Clear Cell Sarcoma of Soft Tissue, Recurrent Ewing Sarcoma, Recurrent Hepatoblastoma, Recurrent Hepatocellular Carcinoma, Recurrent Kidney Wilms Tumor, Recurrent Malignant Solid Neoplasm, Recurrent Osteosarcoma, Recurrent Primary Malignant Central Nervous System Neoplasm, Recurrent Renal Cell Carcinoma, Recurrent Rhabdomyosarcoma, Recurrent Soft Tissue Sarcoma, Recurrent Thyroid Gland Medullary Carcinoma, Refractory Adrenal Cortical Carcinoma, Refractory Alveolar Soft Part Sarcoma, Refractory Clear Cell Sarcoma of Soft Tissue, Refractory Ewing Sarcoma, Refractory Hepatoblastoma, Refractory Hepatocellular Carcinoma, Refractory Malignant Solid Neoplasm, Refractory Osteosarcoma, Refractory Primary Central Nervous System Neoplasm, Refractory Primary Malignant Central Nervous System Neoplasm, Refractory Renal Cell Carcinoma, Refractory Rhabdomyosarcoma, Refractory Soft Tissue Sarcoma, Refractory Thyroid Gland Medullary Carcinoma, Refractory Wilms Tumor, Renal Cell Carcinoma, Rhabdomyosarcoma, Soft Tissue Sarcoma, Solid Neoplasm, Thyroid Gland Medullary Carcinoma, Wilms Tumor
06/21
06/25
NCT01466036: Cabozantinib in Advanced Pancreatic Neuroendocrine and Carcinoid Tumors

Checkmark ASCO 2014
May 2014 - May 2014: ASCO 2014
Completed
2
61
US
Cabozantinib, XL184
Dana-Farber Cancer Institute
Carcinoid Tumor, Pancreatic Neuroendocrine Tumor
08/21
12/23
2021-000986-34: Cabozantinib in combination with Avelumab in patients refractory to standard chemotherapy with advanced neuroendocrine neoplasias G3 (NEN G3). Cabozantinib in Kombination mit Avelumab bei Patienten mit fortgeschrittenen neuroendokrinen Neoplasien G3 (NEN G3), welche refraktär auf eine Standard-Chemotherapie sind.

Not yet recruiting
2
30
Europe
Avelumab, Cabozantinib, MSB0010718C, Concentrate for solution for infusion, Film-coated tablet, Bavencio 20 mg/ml Konzentrat, Cabometyx 20 mg Filmtabletten, Cabometyx 40 mg Filmtabletten
University Medical Center of the Johannes Gutenberg-University Mainz, Ipsen Pharma GmbH, Merck KGaA
Advanced neuroendocrine neoplasias G3 (NEN G3) (excluding SCLC and Merkel cell carcinomas) Fortgeschrittene neuroendokrine Neoplasien G3 (NEN G3) (ausgenommen SCLC und Merkelzellkarzinome), neuroendocrine cancer neuroendokriner Krebs, Diseases [C] - Cancer [C04]
 
 
2020-002366-13: Combination of pembrolizumab and cabozantinib in patients with advanced sarcomas Association du Pembrolizumab et du Cabozantinib chez les patients porteurs d’un sarcome avancé

Not yet recruiting
2
119
Europe
PEMBROLIZUMAB, CABOZANTINIB, MK-3475, XL184, Solution for infusion, Film-coated tablet, KEYTRUDA, CABOMETYX
Institut Bergonié, Groupement Interrégional de Recherche Clinique et d’Innovation Sud-ouest Outre-mer Hospitalier, IPSEN PHARMA
Advanced /metastatic sarcomas: undifferentiated pleomorphic sarcoma, osteosarcoma and Ewing sarcoma Sarcomes localement avancés et/ou métastatiques : sarcomes indifférenciés, ostéosarcomes et sarcomes d’Ewing, Advanced /metastatic sarcomas: undifferentiated pleomorphic sarcoma, osteosarcoma and Ewing sarcoma Sarcomes localement avancés et/ou métastatiques : sarcomes indifférenciés, ostéosarcomes et sarcomes d’Ewing, Diseases [C] - Cancer [C04]
 
 
2021-005549-34: Cabo-POLARIS. Etude de phase 2 prospective multicentrique en ouvert pour évaluer la durée de traitement par cabozantinib chez les patients atteints de carcinome rénal métastatique ou localement avancé en hémodialyse (HD).

Not yet recruiting
2
24
Europe
Cabometyx, Buccal tablet, Cabozantinib (Cabometyx)
CHU Besançon, CHU Besançon, IPSEN
carcinome à cellules rénales avancé ou métastatique., cancer du rein avancé ou métastatique, Diseases [C] - Cancer [C04]
 
 
NF105-CABO, NCT02101736: Cabozantinib for Plexiform Neurofibromas (PN) in Subjects With NF1 in Children and Adults

Completed
2
45
US
Cabozantinib, XL184, Cometriq
University of Alabama at Birmingham
NF1, Neurofibromatosis, Plexiform Neurofibromas
02/22
02/22
NCT01979393 / 2013-000762-11: IRCI Gynae Sarcomas, High Grade Uterine Sarcoma

Active, not recruiting
2
58
Europe
Cabozantinib, Placebo
European Organisation for Research and Treatment of Cancer - EORTC, Gynecologic Oncology Group, NHS Greater Glasgow and Clyde
Uterine Sarcoma
03/22
05/24
2019-001075-36: Study to evaluate the safety, tolerability and efficacy of Cabozantinib in patients with hepatocellular carcinoma and impaired liver function. Studie zur Evaluierung der Sicherheit, Verträglichkeit und Wirksamkeit von Cabozantinib in Patienten mit Leberkarzinom und eingeschränkter Leberfunktion.

Not yet recruiting
2
20
Europe
Film-coated tablet, Cabometyx 20 mg Filmtabletten, Cabometyx 40 mg Filmtabletten
Universitätsmedizin Mainz, Ipsen Pharma GmbH
Hepatocellular carcinoma (HCC) Hepatozelluläres Karzinom (HCC), Liver carcinoma Leberkarzinom, Diseases [C] - Cancer [C04]
 
 
2022-000391-19: Study on Cabozantinib in subjects with recurrent or progressive glioblastoma with c-MET hyperexpression Studio su Cabozantinib in pazienti affetti da glioblastoma ricorrente o in progressione con iperespressione di c-MET

Not yet recruiting
2
40
Europe
Cabozantinib, [Cabozantinib], Film-coated tablet, CABOMETYX - 40 MG- COMPRESSA RIVESTITA CON FILM- USO ORALE- FLACONE (HDPE)- 30 COMPRESSE, CABOMETYX - 60 MG- COMPRESSA RIVESTITA CON FILM- USO ORALE- FLACONE (HDPE)- 30 COMPRESSE, CABOMETYX - 20 MG- COMPRESSA RIVESTITA CON FILM- USO ORALE- FLACONE (HDPE)- 30 COMPRESSE
AZIENDA OSPEDALIERA "S. MARIA", IPSEN SPA
recurrent or progressive glioblastoma with c-MET hyperexpression glioblastoma ricorrente o in progressione con iperespressione di c-MET, recurrent or progressive glioblastoma after standard treatment, characterized by hyperexpression of c-MET glioblastoma ricorrente o in progressione dopo terapia standard, caratterizzato da iperespressione di c-MET, Diseases [C] - Cancer [C04]
 
 
NCT02041260: A Phase II Trial of Cabozantinib for the Treatment of Radioiodine (RAI)-Refractory Differentiated Thyroid Carcinoma (DTC) in the First-line Setting

Checkmark For 1L treatment of metastatic radioiodine-refractory differentiated thyroid carcinoma
Feb 2018 - Feb 2018: For 1L treatment of metastatic radioiodine-refractory differentiated thyroid carcinoma
Active, not recruiting
2
43
US
Cabozantinib
Thomas Jefferson University
Differentiated Thyroid Cancer (DTC), Poorly Differentiated Thyroid Cancer
05/22
05/22
NCT03468985: Nivolumab, Cabozantinib S-Malate, and Ipilimumab in Treating Patients With Recurrent Stage IV Non-small Cell Lung Cancer

Completed
2
3
US
Cabozantinib, Cabozantinib s-malate, XL-184, EXEL-7184, EXEL-02977184, Cabometyx®, Ipilimumab, Anti-CTLA-4 monoclonal antibody, MDX-010, Yervoy, Nivolumab, BMS-936558, MDX1106
National Cancer Institute (NCI)
Metastatic Lung Non-Squamous Non-Small Cell Carcinoma, Recurrent Lung Non-Squamous Non-Small Cell Carcinoma, Stage IV Lung Non-Small Cell Cancer AJCC v7
05/22
12/22
CaboPen, NCT03943602: Cabozantinib in Patients With Advanced Penile Squamous Cell Carcinoma (PSCC)

Recruiting
2
37
Europe
Cabozantinib, CABOMETYX
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Penile Squamous Cell Carcinoma
06/22
09/22
2021-000027-12: Immunological variables associated to ICI toxicity in cancer patients

Not yet recruiting
2
441
Europe
atezolizumab, avelumab, cisplatin, axitinib, bevacizumab, cabozantinib, carboplatin, cemiplimab, durvalumab, etoposide, 5-Fluorouracil, ipilimumab, nab-paclitaxel, nivolumab, oxaliplatin, paclitaxel, pembrolizumab, pemetrexed, Concentrate for solution for infusion, Film-coated tablet, Concentrate for solution for injection, Concentrate and solvent for solution for infusion, Solution for injection/infusion, Powder for suspension for injection, Concentrate for concentrate for solution for infusion
Institut Jules Bordet, Les amis de Bordet, Fondation Lambeau-Marteaux,, FNRS Télévie
solid tumour, solid tumour, Diseases [C] - Cancer [C04]
 
 
UNICAB, NCT03685448: ANZUP - Non-clear Cell Post Immunotherapy CABozantinib

Recruiting
2
48
RoW
Cabozantinib, Cabometyx
Australian and New Zealand Urogenital and Prostate Cancer Trials Group
Renal Cell Carcinoma, Papillary Renal Cell Carcinoma Type 1, Papillary Renal Cell Carcinoma Type 2, Chromophobe Renal Cell Carcinoma, Sarcomatoid Renal Cell Carcinoma, Xp11.2 Translocation-Related Renal Cell Carcinoma
10/22
04/24
NCT05007613: Second-line Cabozantinib and Atezolizumab in Patients With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma

Completed
2
24
RoW
Cabozantinib 40 MG, Cabometyx, Atezolizumab Injection, Tecentriq
National Taiwan University Hospital, Ipsen, Roche Pharma AG
Esophageal Cancer, Metastatic Cancer, Squamous Cell Carcinoma
07/24
12/24
CABOCOL, NCT04205799 / 2019-002184-97: Cabozantinib for Advanced or Metastatic Cervical Carcinoma After Platinum Treatment Failure

Completed
2
57
Europe
Cabozantinib
Centre Francois Baclesse
Advanced/Metastatic Cervical Cancer
01/23
01/23
ARCADIA, NCT03824691: hARnessing CAbozantinib and Durvalumab Immuno-oncology Association: Study"

Recruiting
2
122
Europe
Cabozantinib, CABOMETYX, Durvalumab, Imfinzi
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Bladder Carcinoma
02/23
02/23
ACTION, NCT04316182 / 2014-001333-88: Cabozantinib in Patients With Hepatocellular Carcinoma

Completed
2
24
Europe
Cabozantinib, Cabometix
Fundacion Clinic per a la Recerca Biomédica, Apices Soluciones S.L.
Hepatocellular Carcinoma
02/23
02/23
NCT04714697: Cabozantinib as Subsequent Therapy to an Immune Checkpoint Based Therapy in Renal Cell Carcinoma

Not yet recruiting
2
201
RoW
Cabometyx
Asan Medical Center, Ipsen
Renal Cell Cancer
02/23
02/25
NCT04091750: Nivolumab/Ipilimumab Plus Cabozantinib in Patients With Unresectable Advanced Melanoma

Active, not recruiting
2
14
US
Nivolumab, Opdivo, Ipilimumab, Yervoy, Cabozantinib, Cabometyx
Georgetown University, MedStar Franklin Square Medical Center, Hackensack Meridian Health, Exelixis
Melanoma
08/23
12/25
2022-002419-48: Biomarker Phase II Study Of Cabozantinib In Advanced Radioactive-Iodine Refractory Differentiated Thyroid Cancer. Estudio de fase II con biomarcadores de cabozantinib en cáncer de tiroides diferenciado avanzado refractario al yodo radiactivo.

Not yet recruiting
2
41
Europe
Capsule, CABOMETYX
Grupo Español de Tumores Neuroendocrinos y Endocrinos (GETNE), IPSEN
Patients with radioiodine-refractory differentiated thyroid cancer (DTC). Pacientes con cáncer diferenciado de tiroides (DTC) refractario al yodo radioactivo., Patients thyroids cancer Pacientes con cáncer de tiroides, Diseases [C] - Cancer [C04]
 
 
NCT05039736: A Phase II Study to Evaluate the Effects of Sequential Therapy With the Anti c-MET/VEGFR Tyrosine Kinase Inhibitor (TKI), Cabozantinib, Followed by an Anti-PD-1 Antibody (Nivolumab) in Patients With Advanced HCC Who Progressed on First-line Therapy

Withdrawn
2
30
NA
Cabozantinib, XL-184, XL184, Nivolumab, BMS-936558, Opdivo
M.D. Anderson Cancer Center, Exelixis
Hepatocellular Carcinoma, Liver Cancer
05/23
05/23
CaboPoint, NCT03945773 / 2018-002820-18: Study of Cabozantinib as 2nd Line Treatment in Subjects With Locally Advanced or Metastatic Renal Cell Carcinoma (RCC) With a Clear-Cell Component Who Progressed After 1st Line Treatment With Checkpoint Inhibitors

Active, not recruiting
2
127
Europe
Cabozantinib, Cabometyx
Ipsen
Locally Advanced or Metastatic Renal Cell Carcinoma
05/23
12/30
NCT04164979: Ph II Study of Cabozantinib With Pembrolizumab in Metastatic Gastric and Gastroesophageal Adenocarcinoma

Active, not recruiting
2
20
US
Cabozantinib, CABOMETYX, COMETRIQ, Pembrolizumab, KEYTRUDA
University of California, Irvine, Exelixis
Gastric Adenocarcinoma, GastroEsophageal Cancer
11/23
12/24
Immunocabo, NCT04435977 / 2019-002860-29: Efficacy and Safety of Cabozantinib in Patients With Hepatocellular Carcinoma

Recruiting
2
46
Europe
Cabozantinib 60 MG
Istituto Clinico Humanitas, Ipsen SpA
Hepatocarcinoma
06/23
09/23
CABOMAYOR, NCT04134390 / 2019-001639-30: Study of Cabozantinib Efficacy, Safety and Tolerability in Metastatic Renal Carcinoma in Aged Fragile Patients: Study

Completed
2
25
Europe
Cabozantinib
Spanish Oncology Genito-Urinary Group, Apices Soluciones S.L.
Old Age; Debility, Renal Carcinoma Metastatic
11/23
11/23
NCT03239015: Efficacy and Safety of Precision Therapy in Refractory Tumor

Recruiting
2
300
RoW
Gefitinib, Erlotinib, Afatinib, Trastuzumab, Oxazolidine, Olaparib, Everolimus, Cabozantinib, Vemurafenib, Dabrafenib, Palbociclib, PD-1/L1 inhibitor plus anti-angiogenic agent
Baodong Qin
Rare Tumor, Refractory Tumor
06/23
12/23
CaboCHILD, NCT04454762: A Study to Evaluate the Safety, Tolerability and Efficacy of Cabozantinib in Patients With Hepatocellular Carcinoma and Impaired Liver Function

Recruiting
2
20
Europe
Cabozantinib, Cabometyx
Johannes Gutenberg University Mainz, Interdisciplinary Center Clinical Trials (IZKS), University Medical Center Mainz
Hepatocellular Carcinoma
08/23
02/24
CaboTx, NCT04204850: Cabozantinib to Treat Recurrent Liver Cancer Post Transplant

Recruiting
2
20
Canada
Cabozantinib, CABOMETYX
University Health Network, Toronto, Ipsen
Hepatocellular Carcinoma, Recurrent Cancer, Liver Transplant
08/25
12/25
MERIDIAN, NCT05265988: Multiparametric Assessment of Bone Response in mCRPC Patients Treated With Cabozantinib

Completed
2
32
Europe
Cabozantinib, Cabozantinib 40/20 mg tablet
Alfredo Berruti
Carcinoma Prostate
06/24
06/24
NCT03367741: Cabozantinib S-malate and Nivolumab in Treating Patients With Advanced, Recurrent, or Metastatic Endometrial Cancer

Active, not recruiting
2
84
Canada, US
Biopsy Procedure, Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Cabozantinib S-malate, BMS-907351, Cabometyx, Cometriq, XL 184, XL-184, XL184, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Nivolumab, ABP 206, BCD-263, BMS 936558, BMS-936558, BMS936558, CMAB819, MDX 1106, MDX-1106, MDX1106, NIVO, Nivolumab Biosimilar ABP 206, Nivolumab Biosimilar BCD-263, Nivolumab Biosimilar CMAB819, ONO 4538, ONO-4538, ONO4538, Opdivo
National Cancer Institute (NCI)
Advanced Endometrial Carcinoma, Metastatic Endometrial Carcinoma, Recurrent Endometrial Carcinoma, Stage III Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8, Stage IV Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8
12/25
12/25
CABRAMET, NCT03967522: Evaluation of Cabozantinib in Metastatic Renal Cell Carcinoma (mRCC) With Brain Metastases

Completed
2
26
Europe
Cabozantinib
Centre Leon Berard
Metastatic Renal Cell Carcinoma
10/24
11/24
LOLA, NCT04427787 / 2019-004506-10: A Trial Aiming to Assess the Safety and Activity of the Combination of Cabozantinib Plus Lanreotide in GEP and NET

Recruiting
2
69
Europe
Cabozantinib, Cabometyx, Lanreotide, IPSTYL
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Metastatic Well Differentiated Neuroendocrine Neoplasm, Neuroendocrine Tumors
11/23
11/23
NCT04200443: Cabozantinib and Temozolomide for the Treatment of Unresectable or Metastatic Leiomyosarcoma or Other Soft Tissue Sarcoma

Active, not recruiting
2
72
US
Cabozantinib, Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration, Temozolomide, CCRG-81045, Imidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide, 3, 4-dihydro-3-methyl-4-oxo-, M & B 39831, M and B 39831, Methazolastone, RP-46161, SCH 52365, Temcad, Temodal, Temodar, Temomedac, TMZ
City of Hope Medical Center, National Cancer Institute (NCI)
Metastatic Leiomyosarcoma, Metastatic Soft Tissue Sarcoma, Stage III Uterine Corpus Leiomyosarcoma AJCC v8, Stage IIIA Uterine Corpus Leiomyosarcoma AJCC v8, Stage IIIB Uterine Corpus Leiomyosarcoma AJCC v8, Stage IIIC Uterine Corpus Leiomyosarcoma AJCC v8, Stage IV Uterine Corpus Leiomyosarcoma AJCC v8, Stage IVA Uterine Corpus Leiomyosarcoma AJCC v8, Stage IVB Uterine Corpus Leiomyosarcoma AJCC v8, Unresectable Leiomyosarcoma, Unresectable Soft Tissue Sarcoma
04/25
04/25
CABATEN, NCT04400474: Trial of Cabozantinib Plus Atezolizumab in Advanced and Progressive Neoplasms of the Endocrine System. The Study

Active, not recruiting
2
93
Europe
Cabozantinib 40 mg, Atezolizumab 1200 mg
Grupo Espanol de Tumores Neuroendocrinos, Ipsen, Roche Pharma AG
Neuroendocrine Tumor, Anaplastic Thyroid Cancer, Adenocarcinoma, Pheochromocytoma, Paraganglioma
12/23
03/24
CaboRISE, NCT04522908: Dose Escalation Study of Cabozantinib for Advanced HCC Patients with Preserved Liver Function

Completed
2
40
Europe
Cabozantinib Oral Tablet, CABOMETYX
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, Johann Wolfgang Goethe University Hospital, Prof. Dr. med. Trojan
Hepatocellular Carcinoma (HCC), Second Line Treatment
10/24
10/24
CANOPY, NCT05502315: Study of Cabozantinib and Nivolumab in Metastatic Castration Resistant Prostate Cancer

Recruiting
2
47
US
Cabozantinib, Cabometyx, Nivolumab, Opdivo
Rana McKay, MD, Exelixis, Bristol-Myers Squibb
Castration-resistant Prostate Cancer, Metastatic Cancer
04/26
04/27
NCT05111574: Using Nivolumab Alone or With Cabozantinib to Prevent Mucosal Melanoma Return After Surgery

Recruiting
2
99
Canada, US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Bone Scan, Bone Scintigraphy, Cabozantinib S-malate, BMS-907351, Cabometyx, Cometriq, XL 184, XL-184, XL184, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Echocardiography Test, EC, Echocardiography, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Nivolumab, ABP 206, BCD-263, BMS 936558, BMS-936558, BMS936558, CMAB819, MDX 1106, MDX-1106, MDX1106, NIVO, Nivolumab Biosimilar ABP 206, Nivolumab Biosimilar BCD-263, Nivolumab Biosimilar CMAB819, ONO 4538, ONO-4538, ONO4538, Opdivo, Placebo Administration, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, PT
National Cancer Institute (NCI)
Anal Melanoma, Bladder Melanoma, Cervical Melanoma, Esophageal Melanoma, Gallbladder Melanoma, Head and Neck Mucosal Melanoma, Mucosal Melanoma, Mucosal Melanoma of the Urinary System, Nasopharyngeal Mucosal Melanoma, Oral Cavity Mucosal Melanoma, Penile Mucosal Melanoma, Rectal Melanoma, Recurrent Mucosal Melanoma, Sinonasal Mucosal Melanoma, Urethral Melanoma, Vaginal Melanoma, Vulvar Melanoma
12/25
12/25
NCT04197310: Cabozantinib and Nivolumab for Carcinoid Tumors

Completed
2
19
US
Nivolumab, Opdivo, Cabozantinib, Cometriq, Cabometyx
Dana-Farber Cancer Institute, Bristol-Myers Squibb, Exelixis
Carcinoid Tumor, Carcinoid Tumor of GI System, Neuroendocrine Tumors
12/23
01/24
NCT03899428: Immune Checkpoint Therapy vs Target Therapy in Reducing Serum HBsAg Levels in Patients With HBsAg+ Advanced Stage HCC

Recruiting
2
30
RoW
Durvalumab, IMFINZI®, Sorafenib, Nexavar, BAY43-9006, Lenvatinib, Lenvima, E7080, Regorafenib, Stivarga, BAY73-4506, Cabozantinib, Cabometyx, XL184
Humanity & Health Medical Group Limited
Hepatocellular Carcinoma
12/25
12/25
NCT04472767: Cabozantinib Combined With Ipilimumab/Nivolumab and TACE in Patients With Hepatocellular Carcinoma

Recruiting
2
35
US
Nivolumab, OPDIVO®, Ipilimumab, YERVOY®, Cabozantinib, CABOMETYX®, COMETRIQ, Transarterial Chemoembolization, TACE
University of California, Irvine, Exelixis
Hepatocellular Carcinoma, HCC
06/26
09/27
NCT05052723: Cabozantinib and Pembrolizumab in Metastatic Pancreas

Completed
2
21
US
Cabozantinib, Pembrolizumab
Joseph Kim, Exelixis, Merck Sharp & Dohme LLC
Pancreatic Cancer
11/24
11/24
CABOTEM, NCT04893785 / 2020-001898-78: A Trial Evaluating the Activity and Safety of Combination Between Cabozantinib and Temozolomide in Lung and GEP-NENS Progressive After Everolimus, Sunitinib or PRRT

Recruiting
2
35
Europe
Cabozantinib and Temozolomide
National Cancer Institute, Naples
Lung Neuroendocrine Neoplasm, GEP Neuroendocrine Tumor
01/25
12/26
NCT03468218: Pembrolizumab & Cabozantinib in Patients With Head and Neck Squamous Cell Cancer

Checkmark Data from a study in combination with Cabometyx for recurrent or metastatic HNSCC at ASCO 2022
May 2022 - May 2022: Data from a study in combination with Cabometyx for recurrent or metastatic HNSCC at ASCO 2022
Active, not recruiting
2
36
US
Cabozantinib, Cabometyx, Cometriq, Pembrolizumab, Keytruda, Lambrolizumab, MK-3475, SCH 900475
Emory University, Exelixis, National Institutes of Health (NIH), National Cancer Institute (NCI)
Metastatic Head and Neck Carcinoma, Paranasal Sinus Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma, Recurrent Hypopharyngeal Squamous Cell Carcinoma, Recurrent Laryngeal Squamous Cell Carcinoma, Recurrent Oral Cavity Squamous Cell Carcinoma, Recurrent Oropharyngeal Squamous Cell Carcinoma, Stage IV Hypopharyngeal Squamous Cell Carcinoma AJCC v7, Stage IV Laryngeal Squamous Cell Carcinoma AJCC v7, Stage IV Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7, Stage IV Oropharyngeal Squamous Cell Carcinoma AJCC v7, Stage IVA Hypopharyngeal Squamous Cell Carcinoma AJCC v7, Stage IVA Laryngeal Squamous Cell Carcinoma AJCC v7, Stage IVA Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7, Stage IVA Oropharyngeal Squamous Cell Carcinoma AJCC v7, Stage IVB Hypopharyngeal Squamous Cell Carcinoma AJCC v7, Stage IVB Laryngeal Squamous Cell Carcinoma AJCC v7, Stage IVB Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7, Stage IVB Oropharyngeal Squamous Cell Carcinoma AJCC v7, Stage IVC Hypopharyngeal Squamous Cell Carcinoma AJCC v7, Stage IVC Laryngeal Squamous Cell Carcinoma AJCC v7, Stage IVC Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7, Stage IVC Oropharyngeal Squamous Cell Carcinoma AJCC v7, Unresectable Head and Neck Squamous Cell Carcinoma
05/22
10/25
NCT03914300: Testing the Combination of Cabozantinib, Nivolumab, and Ipilimumab (CaboNivoIpi) for Advanced Differentiated Thyroid Cancer

Active, not recruiting
2
9
US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Cabozantinib S-malate, BMS-907351, Cabometyx, Cometriq, XL 184, XL-184, XL184, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Ipilimumab, Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, BMS 734016, BMS-734016, BMS734016, Ipilimumab Biosimilar CS1002, MDX 010, MDX-010, MDX-CTLA4, MDX010, Yervoy, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Nivolumab, ABP 206, BCD-263, BMS 936558, BMS-936558, BMS936558, CMAB819, MDX 1106, MDX-1106, MDX1106, NIVO, Nivolumab Biosimilar ABP 206, Nivolumab Biosimilar BCD-263, Nivolumab Biosimilar CMAB819, ONO 4538, ONO-4538, ONO4538, Opdivo
National Cancer Institute (NCI)
Differentiated Thyroid Gland Carcinoma, Follicular Variant Thyroid Gland Papillary Carcinoma, Poorly Differentiated Thyroid Gland Carcinoma, Refractory Differentiated Thyroid Gland Carcinoma, Refractory Thyroid Gland Carcinoma, Tall Cell Variant Thyroid Gland Papillary Carcinoma, Thyroid Gland Follicular Carcinoma, Thyroid Gland Oncocytic Carcinoma, Thyroid Gland Papillary Carcinoma
10/24
12/25
NCT05263050: Trial of an Alternative Cabozantinib Dosing Schedule in Metastatic Renal Cell Carcinoma and Neuroendocrine Tumors

Recruiting
2
111
US
Cabozantinib, XL184, Nivolumab, Opdivo
Fox Chase Cancer Center, Exelixis
Metastatic Renal Cell Carcinoma, Clear-cell Metastatic Renal Cell Carcinoma, Neuroendocrine Tumors, Carcinoid Tumor
02/26
02/27
 

Download Options